

David J Greenblatt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9440794/publications.pdf>

Version: 2024-02-01

710
papers

34,887
citations

2802

94
h-index

8866

145
g-index

726
all docs

726
docs citations

726
times ranked

14841
citing authors

#	ARTICLE	IF	CITATIONS
1	Mechanism of dasabuvir inhibition of acetaminophen glucuronidation. <i>Journal of Pharmacy and Pharmacology</i> , 2022, 74, 131-138.	2.4	3
2	Brexipiprazole Pharmacokinetics in CYP2D6 Poor Metabolizers: Using Physiologically Based Pharmacokinetic Modeling to Optimize Time to Effective Concentrations. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 66-75.	2.0	5
3	Impact of Obesity on Brexpiprazole Pharmacokinetics: Proposal for Improved Initiation of Treatment. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 55-65.	2.0	6
4	Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 925-927.	2.0	5
5	Drug Disposition in Subjects With Obesity: The Research Work of Darrell R. Abernethy. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 1350-1363.	2.0	12
6	Slow Accumulation and Elimination of Diazepam and Its Active Metabolite With Extended Treatment in the Elderly. <i>Journal of Clinical Pharmacology</i> , 2021, 61, 193-203.	2.0	9
7	Effect of lipophilicity on drug distribution and elimination: Influence of obesity. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3197-3205.	2.4	33
8	The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 1015-1024.	1.6	2
9	Diazepam in the Elderly: Looking Back, Ahead, and at the Evidence. <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 215-219.	1.4	7
10	Comment on the Next Chapter of the <i>Journal of Clinical Psychopharmacology</i> . <i>Journal of Clinical Psychopharmacology</i> , 2020, 40, 528-528.	1.4	0
11	Effect of First-Line Antituberculosis Therapy on Nevirapine Pharmacokinetics in Children Younger than Three Years Old. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	2
12	Public Health Risk of Designer Psychotropic Drugs: Should PHASE Be Phased In?. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 1175-1176.	4.7	0
13	Methadone Disposition: Implementing Lessons Learned. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 1044-1048.	2.0	14
14	Erythromycin acts through the ghrelin receptor to attenuate inflammatory responses in chondrocytes and maintain joint integrity. <i>Biochemical Pharmacology</i> , 2019, 165, 79-90.	4.4	5
15	Prolonged therapy with the anticonvulsant carbamazepine leads to increased plasma clearance of fentanyl. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 982-987.	2.4	12
16	Designer Benzodiazepines: A Review of Published Data and Public Health Significance. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 266-269.	1.6	28
17	Zolpidem and Gender: Are Women Really At Risk?. <i>Journal of Clinical Psychopharmacology</i> , 2019, 39, 189-199.	1.4	42
18	Effect of Rifampin-Isoniazid-Containing Antituberculosis Therapy on Efavirenz Pharmacokinetics in HIV-Infected Children 3 to 14 Years Old. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 63, .	3.2	6

#	ARTICLE	IF	CITATIONS
19	Resveratrol glucuronidation <i>in vitro</i> : potential implications of inhibition by probenecid. <i>Journal of Pharmacy and Pharmacology</i> , 2019, 71, 371-378.	2.4	4
20	Ketoconazole and Liver Injury: A Five-Year Update. <i>Clinical Pharmacology in Drug Development</i> , 2019, 8, 6-8.	1.6	8
21	Opportunistic Journals in the Clinical Pharmacology Space. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 567-571.	2.0	4
22	Gabapentin and Pregabalin for the Treatment of Anxiety Disorders. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 228-232.	1.6	39
23	Inhibitory effects of sulfonylureas and non-steroidal anti-inflammatory drugs on <i>in vitro</i> metabolism of canagliflozin in human liver microsomes. <i>Biopharmaceutics and Drug Disposition</i> , 2018, 39, 135-142.	1.9	2
24	Opioid Prescribing: What Are the Numbers?. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 6-8.	1.6	3
25	Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. <i>Clinical Therapeutics</i> , 2018, 40, 64-73.	2.5	11
26	Opportunistic Journals in the Clinical Pharmacology Space. <i>Clinical Pharmacology in Drug Development</i> , 2018, 7, 353-357.	1.6	3
27	Vortioxetine Disposition in Obesity. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 172-179.	1.4	15
28	<i>In vitro</i> inhibition of human UGT isoforms by ritonavir and cobicistat. <i>Xenobiotica</i> , 2018, 48, 764-769.	1.1	13
29	Impaired Rivaroxaban Clearance in Mild Renal Insufficiency With Verapamil Coadministration: Potential Implications for Bleeding Risk and Dose Selection. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 533-540.	2.0	39
30	Is There Always a Right or Wrong?. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 545-546.	1.4	0
31	Therapeutic Drug Monitoring of Antidepressants. <i>Handbook of Experimental Pharmacology</i> , 2018, 250, 115-133.	1.8	9
32	International Task Force on Benzodiazepines. <i>Psychotherapy and Psychosomatics</i> , 2018, 87, 193-194.	8.8	26
33	The Prescription of Benzodiazepines for Panic Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 283-285.	1.4	17
34	Persistence of a Posaconazole-Mediated Drug-Drug Interaction With Ranolazine After Cessation of Posaconazole Administration: Impact of Obesity and Implications for Patient Safety. <i>Journal of Clinical Pharmacology</i> , 2018, 58, 1436-1442.	2.0	14
35	Update on Psychotropic Drug Prescribing in the United States. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 1-4.	1.4	32
36	Sustained Impairment of Lurasidone Clearance After Discontinuation of Posaconazole. <i>Journal of Clinical Psychopharmacology</i> , 2018, 38, 289-295.	1.4	23

#	ARTICLE	IF	CITATIONS
37	Mechanisms and Consequences of Drug-Drug Interactions. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 118-124.	1.6	18
38	The <i>Journal of Clinical Pharmacology</i> , <i>Clinical Pharmacology in Drug Development</i> , and the Impact Factor. <i>Clinical Pharmacology in Drug Development</i> , 2017, 6, 218-219.	1.6	0
39	Inhibition of human cytochromes P450 <i>in vitro</i> by ritonavir and cobicistat. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1786-1793.	2.4	40
40	Mechanism of <i>in-vitro</i> inhibition of UGT1A1 by paritaprevir. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1794-1801.	2.4	8
41	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through <i>in-vitro</i> inhibition studies. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 69, 1762-1772.	2.4	39
42	The Impact Non-Factor. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 389-390.	1.4	5
43	Recent Recall of a Generic Form of Extended-Release Paliperidone. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 493-494.	1.4	0
44	Inhibitory Effects of Selected Antituberculosis Drugs on Common Human Hepatic Cytochrome P450 and UDP-glucuronosyltransferase Enzymes. <i>Drug Metabolism and Disposition</i> , 2017, 45, 1035-1043.	3.3	18
45	Race, Gender, and Genetic Polymorphism Contribute to Variability in Acetaminophen Pharmacokinetics, Metabolism, and Protein-Adduct Concentrations in Healthy African-American and European-American Volunteers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 431-440.	2.5	49
46	Meldonium (Mildronate): A Performance-Enhancing Drug?. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 167-169.	1.6	13
47	Evidence-based choice of ritonavir as index CYP3A inhibitor in drug-drug interaction studies. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 152-156.	2.0	26
48	Use of Antipsychotics for the Treatment of Behavioral Symptoms of Dementia. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1048-1057.	2.0	22
49	Ketoconazole-Associated Liver Injury in Drug-Drug Interaction Studies in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1196-1202.	2.0	12
50	Body Size Changes Among National Collegiate Athletic Association New England Division III Football Players, 1956-2014: Comparison With Age-Matched Population Controls. <i>Journal of Athletic Training</i> , 2016, 51, 373-381.	1.8	8
51	<i>Clinical Pharmacology in Drug Development</i> : Five Years in the Books. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 432-434.	1.6	0
52	Pharmacokinetics cannot explain the increased effective dose requirement for morphine and midazolam in rats during their extended administration alone or in combination. <i>Journal of Pharmacy and Pharmacology</i> , 2016, 69, 82-88.	2.4	7
53	Antidepressant-Associated Hyponatremia in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 545-549.	1.4	18
54	Stereo- <i>Psychopharmacology</i> : The Case of Citalopram and Escitalopram. <i>Clinical Pharmacology in Drug Development</i> , 2016, 5, 331-335.	1.6	6

#	ARTICLE	IF	CITATIONS
55	Elements of a Good Scientific Paper. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 539-541.	1.4	1
56	Pharmacokinetics and Pharmacodynamics for Medical Students: A Proposed Course Outline. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 1180-1195.	2.0	10
57	A randomized trial of mexiletine in ALS. <i>Neurology</i> , 2016, 86, 1474-1481.	1.1	72
58	Favipiravir inhibits acetaminophen sulfate formation but minimally affects systemic pharmacokinetics of acetaminophen. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 1076-1085.	2.4	26
59	Preclinical rodent toxicity studies for long term use of ceftriaxone. <i>Toxicology Reports</i> , 2015, 2, 1396-1403.	3.3	7
60	Clinical pharmacology in drug development – an update. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 243-244.	1.6	2
61	Inhibition of 2-methoxyestradiol glucuronidation by probenecid. <i>Journal of Pharmacy and Pharmacology</i> , 2015, 67, 1585-1592.	2.4	7
62	A soft benzodiazepine. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 81-82.	1.6	2
63	Regression and Correlation. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 161-162.	1.6	4
64	Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450 3A in drug-drug interaction studies. <i>British Journal of Clinical Pharmacology</i> , 2015, 80, 342-350.	2.4	83
65	American College of Clinical Pharmacology commentary on the Strategic Plan 2010-2014 Progress Report from the Office of Dietary Supplements, National Institutes of Health. <i>Journal of Clinical Pharmacology</i> , 2015, 55, 723-724.	2.0	1
66	Altered Drug Disposition Following Bariatric Surgery: A Research Challenge. <i>Clinical Pharmacokinetics</i> , 2015, 54, 573-579.	3.5	38
67	Aspartame – Is there new information?. <i>Clinical Pharmacology in Drug Development</i> , 2015, 4, 1-1.	1.6	2
68	Adverse performance effects of acute lorazepam administration in elderly long-term users: Pharmacokinetic and clinical predictors. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2015, 56, 129-135.	4.8	22
69	The Pharmacovigilance Syndrome. <i>Journal of Clinical Psychopharmacology</i> , 2015, 35, 361-363.	1.4	21
70	Sleep-promoting medications: Weighing the hazards of use versus non-use. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 167-169.	1.6	5
71	The ketoconazole legacy. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 1-3.	1.6	21
72	Gender differences in pharmacokinetics and pharmacodynamics of zolpidem following sublingual administration. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 282-290.	2.0	86

#	ARTICLE	IF	CITATIONS
73	Pharmacokinetics of Zolpidem from Sublingual Zolpidem Tartrate Tablets In Healthy Elderly Versus Non-Elderly Subjects. <i>Drugs and Aging</i> , 2014, 31, 731-736.	2.7	12
74	Antiretroviral boosting by cobicistat, a structural analog of ritonavir. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 335-337.	1.6	15
75	Drug interactions with methadone: Time to revise the product label. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 249-251.	1.6	13
76	A Tribute to Dr. Hermann R. Ochs, 1943â€“2013. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 669-670.	1.4	0
77	Editorsâ€™ Note Regarding Publication Delay. <i>Journal of Clinical Psychopharmacology</i> , 2014, 34, 671.	1.4	0
78	Isoniazid Mediates the <i>CYP2B6</i> Genotype-Dependent Interaction between Efavirenz and Antituberculosis Drug Therapy through Mechanism-Based Inactivation of CYP2A6. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 4145-4152.	3.2	23
79	Characterization of cognitive dysfunction in Sjögrenâ€™s syndrome patients. <i>Clinical Rheumatology</i> , 2014, 33, 511-521.	2.2	15
80	Systemic pharmacokinetics and cerebrospinal fluid uptake of intravenous ceftriaxone in patients with amyotrophic lateral sclerosis. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1180-1187.	2.0	14
81	Candidate Gene Polymorphisms in Patients with Acetaminophen-Induced Acute Liver Failure. <i>Drug Metabolism and Disposition</i> , 2014, 42, 28-32.	3.3	53
82	In Vitro Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 133-135.	4.7	16
83	Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. <i>Lancet Neurology</i> , The, 2014, 13, 1083-1091.	10.2	187
84	Volume of distribution â€“ Again. <i>Clinical Pharmacology in Drug Development</i> , 2014, 3, 419-420.	1.6	5
85	Liver injury associated with ketoconazole: Review of the published evidence. <i>Journal of Clinical Pharmacology</i> , 2014, 54, 1321-1329.	2.0	63
86	Effect of a herbal extract containing curcumin and piperine on midazolam, flurbiprofen and paracetamol (acetaminophen) pharmacokinetics in healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 450-462.	2.4	65
87	Comparison of Pharmacokinetic Profiles of Zolpidem Buffered Sublingual Tablet and Zolpidem Oral Immediate-Release Tablet: Results from a Single-Center, Single-Dose, Randomized, Open-Label Crossover Study in Healthy Adults. <i>Clinical Therapeutics</i> , 2013, 35, 604-611.	2.5	37
88	Grapefruitâ€“medication interactions. <i>Cmaj</i> , 2013, 185, 507.1-507.	2.0	4
89	The UDP-Glucuronosyltransferase (UGT) 1A Polymorphism c.2042C>G (rs8330) Is Associated with Increased Human Liver Acetaminophen Glucuronidation, Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio, and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure. <i>Journal of Pharmacology and Experimental Therapeutics</i> . 2013. 345. 297-307.	2.5	75
90	The Seventy-Kilogram Fantasy. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 101-102.	1.6	3

#	ARTICLE	IF	CITATIONS
91	Effect of blueberry juice on clearance of buspirone and flurbiprofen in human volunteers. <i>British Journal of Clinical Pharmacology</i> , 2013, 75, 1041-1052.	2.4	14
92	Hepatic Clearance of Drugs in Patients With Renal Insufficiency. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 295-297.	1.6	11
93	Influence of food on pharmacokinetics of zolpidem from fast dissolving sublingual zolpidem tartrate tablets. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1194-1198.	2.0	8
94	Into the Second Year. <i>Clinical Pharmacology in Drug Development</i> , 2013, 2, 1-1.	1.6	6
95	Design and Initial Results of a Multi-Phase Randomized Trial of Ceftriaxone in Amyotrophic Lateral Sclerosis. <i>PLoS ONE</i> , 2013, 8, e61177.	2.5	93
96	Evidence for epigenetic regulation of UGT1A1 protein expression and activity in healthy human livers. <i>FASEB Journal</i> , 2013, 27, 270.5.	0.5	0
97	Mechanism-based inhibition of human Cytochrome P450-3A activity by grapefruit hybrids having low furanocoumarin content. <i>Xenobiotica</i> , 2012, 42, 1163-1169.	1.1	14
98	From Disordered Eating to Addiction. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 376-389.	1.4	42
99	Pharmacokinetic evaluation of eszopiclone: clinical and therapeutic implications. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 1609-1618.	3.3	18
100	Regulatory and Scientific Aspects of Drug-Drug Interaction Studies. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 43-44.	1.6	1
101	Explaining Some Journal Requirements. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 119-120.	1.6	4
102	Clinical Pharmacology in Drug Development. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 3-3.	1.6	2
103	Pomegranate Juice and Pomegranate Extract Do Not Impair Oral Clearance of Flurbiprofen in Human Volunteers: Divergence From In Vitro Results. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 651-657.	4.7	25
104	Drug Interaction Studies With CYP3A Substrates: How Much Inhibitor Pre-exposure Is Needed?. <i>Clinical Pharmacology in Drug Development</i> , 2012, 1, 83-84.	1.6	5
105	Zolpidem for insomnia. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 879-893.	1.8	258
106	Biochemical Basis for Deficient Paracetamol Glucuronidation in Cats: an Interspecies Comparison of Enzyme Constraint in Liver Microsomes. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 49, 446-449.	2.4	42
107	Multiple Human Cytochromes Contribute to Biotransformation of Dextromethorphan In-vitro: Role of CYP2C9, CYP2C19, CYP2D6, and CYP3A. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 50, 997-1004.	2.4	85
108	Mechanism of cytochrome P450-3A inhibition by ketoconazole. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 63, 214-221.	2.4	89

#	ARTICLE	IF	CITATIONS
109	Cerebrospinal fluid uptake and peripheral distribution of centrally acting drugs: Relation to lipid solubility. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 37, 428-431.	2.4	26
110	Translocase of Outer Mitochondrial Membrane 40 Homolog (TOMM40) Poly-T Length Modulates Lorazepam-Related Cognitive Toxicity in Healthy APOE ϵ 4-Negative Elderly. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 544-546.	1.4	10
111	Liquid chromatographic retention of β -adrenoceptor antagonists: an index of lipid solubility. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 36, 400-401.	2.4	14
112	Concentration-independent plasma protein binding of benzodiazepines. <i>Journal of Pharmacy and Pharmacology</i> , 2011, 35, 179-180.	2.4	109
113	Serum concentrations and clinical effects of atorvastatin in patients taking grapefruit juice daily. <i>British Journal of Clinical Pharmacology</i> , 2011, 72, 434-441.	2.4	34
114	Pharmacokinetic profile of SKP-1041, a modified release formulation of zaleplon. <i>Biopharmaceutics and Drug Disposition</i> , 2011, 32, 489-497.	1.9	3
115	Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors. <i>Journal of Clinical Oncology</i> , 2011, 29, 2933-2940.	1.6	89
116	Psychotropic Drug Prescribing in the United States. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 1-3.	1.4	32
117	The effect of grapefruit juice on drug disposition. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2011, 7, 267-286.	3.3	164
118	Modest but Variable Effect of Rifampin on Steady-State Plasma Pharmacokinetics of Efavirenz in Healthy African-American and Caucasian Volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 3527-3533.	3.2	21
119	Clinical Pharmacology and Therapeutics of Antidepressants. , 2011, , 33-124.		9
120	Introduction to Drug-Drug Interactions. , 2011, , 1-10.		6
121	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1229-1239.	2.4	22
122	Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 819-825.	2.4	12
123	Apparent mechanism-based inhibition of human CYP3A in-vitro by lopinavir. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 381-386.	2.4	28
124	Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 963-966.	2.4	1
125	Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 59, 947-953.	2.4	45
126	Pharmacokinetics, bioavailability and effects on electrocardiographic parameters of oral fludarabine phosphate. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 72-81.	1.9	4

#	ARTICLE	IF	CITATIONS
127	Relationship Between Plasma Protease Inhibitor Concentrations and Lipid Elevations in HIV Patients on a Doubleâ€Boosted Protease Inhibitor Regimen (Saquinavir/Lopinavir/Ritonavir). <i>Journal of Clinical Pharmacology</i> , 2010, 50, 392-400.	2.0	7
128	Sources of variability in ketoconazole inhibition of human cytochrome P450 3A<i>in vitro</i>. <i>Xenobiotica</i> , 2010, 40, 713-720.	1.1	30
129	Inhibition of human cytochromes P450 by components of Ginkgo bilobaâ€. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 1039-1044.	2.4	132
130	Effect of Obesity on the Pharmacokinetics of Drugs in Humans. <i>Clinical Pharmacokinetics</i> , 2010, 49, 71-87.	3.5	594
131	Effect of bupropion on CYP2B6 and CYP3A4 catalytic activity, immunoreactive protein and mRNA levels in primary human hepatocytes: comparison with rifampicin. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 55, 1707-1707.	2.4	0
132	A phase I, pharmacokinetic, dosage escalation study of creatine monohydrate in subjects with amyotrophic lateral sclerosis. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , 2010, 11, 508-513.	2.1	30
133	Clinical Studies of Drugâ€Drug Interactions: Design and Interpretation. , 2010, , 625-649.		22
134	Pharmacokinetic Determinants of the Clinical Effects of Benzodiazepine Agonist Hypnotics. , 2010, , 95-118.		8
135	Analysis of Drug Interactions Involving Fruit Beverages and Organic Anionâ€Transporting Polypeptides. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 1403-1407.	2.0	57
136	Role of NADPH-Cytochrome P450 Reductase and Cytochrome-<i>b</i>₅/NADH-<i>b</i>₅ Reductase in Variability of CYP3A Activity in Human Liver Microsomes. <i>Drug Metabolism and Disposition</i> , 2009, 37, 90-96.	3.3	38
137	Evidence for oxazepam as an <i>in vivo</i> probe of UGT2B15: oxazepam clearance is reduced by <i>UGT2B15</i> D85Y polymorphism but unaffected by <i>UGT2B17</i> deletion. <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 721-730.	2.4	64
138	Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4â€dimethylâ€benzisoâ€(2H)â€selenazine (ALTâ€2074), an experimental catalytic mimic of glutathione oxidase.2.4 <i>British Journal of Clinical Pharmacology</i> , 2009, 68, 920-927.		45
139	Propofol Clearance and Volume of Distribution Are Increased in Patients With Major Burns. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 768-772.	2.0	18
140	Short-Term Clarithromycin Administration Impairs Clearance and Enhances Pharmacodynamic Effects of Trazodone but Not of Zolpidem. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 644-650.	4.7	24
141	The Absence of an Interaction Between Warfarin and Cranberry Juice: A Randomized, Doubleâ€Blind Trial. <i>Journal of Clinical Pharmacology</i> , 2009, 49, 824-830.	2.0	44
142	Drugâ€Drug Noninteractions. <i>Cardiovascular Therapeutics</i> , 2009, 27, 226-229.	2.5	8
143	Influence of fruit juices on drug disposition: discrepancies between<i>in vitro</i>and clinical studies. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 381-393.	3.3	65
144	Pharmacokinetics of Efavirenz When Coâ€administered With Rifampin in TB/HIV Coâ€infected Patients: Pharmacogenetic Effect of <i>CYP2B6</i> Variation. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1032-1040.	2.0	41

#	ARTICLE	IF	CITATIONS
145	Pharmacologic Consideration for the Use of Antiretroviral Agents in the Elderly. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1212-1225.	2.0	23
146	Gender Has a Small but Statistically Significant Effect on Clearance of CYP3A Substrate Drugs. <i>Journal of Clinical Pharmacology</i> , 2008, 48, 1350-1355.	2.0	86
147	Ritonavir Greatly Impairs CYP3A Activity in HIV Infection With Chronic Viral Hepatitis. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2008, 49, 358-368.	2.1	33
148	Preparation of Scientific Reports on Pharmacokinetic Drug Interaction Studies. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 369-373.	1.4	11
149	Chapter 11. The CYP3 Family. <i>Issues in Toxicology</i> , 2008, , 354-383.	0.1	19
150	Pomegranate Juice Does Not Impair Clearance of Oral or Intravenous Midazolam, a Probe for Cytochrome P450-3A Activity: Comparison With Grapefruit Juice. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 286-294.	2.0	70
151	Role of CYP3A and CYP2E1 in Alcohol-Mediated Increases in Acetaminophen Hepatotoxicity: Comparison of Wild-Type and Cyp2e1 ^{-/-} Mice. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1223-1231.	3.3	53
152	Comparison of Duloxetine, Escitalopram, and Sertraline Effects on Cytochrome P450 2D6 Function in Healthy Volunteers. <i>Journal of Clinical Psychopharmacology</i> , 2007, 27, 28-34.	1.4	71
153	Age and Gender Effects on the Pharmacokinetics and Pharmacodynamics of Ramelteon, a Hypnotic Agent Acting via Melatonin Receptors MT1 and MT2. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 485-496.	2.0	59
154	Fentanyl Clearance and Volume of Distribution Are Increased in Patients With Major Burns. <i>Journal of Clinical Pharmacology</i> , 2007, 47, 674-680.	2.0	40
155	Human Pregnane X Receptor: Genetic Polymorphisms, Alternative mRNA Splice Variants, and Cytochrome P450 3A Metabolic Activity. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1356-1369.	2.0	22
156	Pharmacokinetic determinants of hypnotic drug action: The art and science of controlling release. <i>Sleep Medicine</i> , 2006, 7, S10-S14.	1.6	3
157	In Vitro Interactions of Water-Soluble Garlic Components with Human Cytochromes P450. <i>Journal of Nutrition</i> , 2006, 136, 806S-809S.	2.9	32
158	Ginkgo biloba Does Not Alter Clearance of Flurbiprofen, a Cytochrome P450 ^{2C9} Substrate. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 214-221.	2.0	52
159	Pharmacologic Management of Dental Anxiety. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 1-3.	1.4	7
160	Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 179-192.	2.0	51
161	Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 125-133.	4.7	80
162	Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: Comparison with ritonavir. <i>Clinical Pharmacology and Therapeutics</i> , 2006, 79, 243-254.	4.7	70

#	ARTICLE	IF	CITATIONS
163	Simple and rapid liquid chromatography method for determination of efavirenz in plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 835, 131-135.	2.3	38
164	Dose-dependent retrograde facilitation of verbal memory in healthy elderly after acute oral lorazepam administration. <i>Psychopharmacology</i> , 2006, 185, 487-494.	3.1	9
165	The effect of chronic lorazepam administration in aging mice. <i>Brain Research</i> , 2006, 1118, 13-24.	2.2	7
166	Acute zolpidem administration produces pharmacodynamic and receptor occupancy changes at similar doses. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 83, 21-27.	2.9	17
167	Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers. <i>Biopharmaceutics and Drug Disposition</i> , 2006, 27, 219-227.	1.9	15
168	FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1198-1207.	3.3	48
169	Dynamics and Kinetics of a Modified-Release Formulation of Zolpidem: Comparison With Immediate-Release Standard Zolpidem and Placebo. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 1469-1480.	2.0	54
170	THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER. <i>Drug Metabolism and Disposition</i> , 2006, 34, 1220-1228.	3.3	71
171	Ritonavir Has Minimal Impact on the Pharmacokinetic Disposition of a Single Dose of Bupropion Administered to Human Volunteers. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 567-576.	2.0	32
172	Balancing efficacy and safety in the use of oral sedation in dental outpatients. <i>Journal of the American Dental Association</i> , 2006, 137, 502-513.	1.5	40
173	A Randomized, Double-Blind Trial of the Interaction between Cranberry Juice and Warfarin.. <i>Blood</i> , 2006, 108, 4125-4125.	1.4	0
174	Identification of Human Cd8+ and Cd4+ Lymphocytes with Unique Drug Resistance Activity by Imaging the Drug Transport Kinetics at the Single Cell Resolution.. <i>Blood</i> , 2006, 108, 3894-3894.	1.4	0
175	Hyperforin Plasma Level as a Marker of Treatment Adherence in the National Institutes of Health Hypericum Depression Trial. <i>Journal of Clinical Psychopharmacology</i> , 2005, 25, 243-249.	1.4	16
176	Kinetics and Dynamics of Intravenous Adinazolam, N-Desmethyl Adinazolam, and Alprazolam in Healthy Volunteers. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 529-537.	2.0	28
177	Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo. <i>Clinical Pharmacology and Therapeutics</i> , 2005, 77, 373-387.	4.7	116
178	UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: II. Functional Impact of the Three Most Common Nonsynonymous UGT1A6 Polymorphisms (S7A, T181A, and R184S). <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1340-1346.	2.5	104
179	Pharmacokinetics and pharmacodynamics of single-dose triazolam: electroencephalography compared with the Digit-Symbol Substitution Test. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 244-248.	2.4	29
180	Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics. <i>British Journal of Clinical Pharmacology</i> , 2005, 60, 486-493.	2.4	51

#	ARTICLE	IF	CITATIONS
181	UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. <i>Hepatology</i> , 2005, 42, 448-457.	7.3	70
182	Cortisol response to diazepam: its relationship to age, dose, duration of treatment, and presence of generalized anxiety disorder. <i>Psychopharmacology</i> , 2005, 178, 1-8.	3.1	54
183	Sex-related elevation in cortisol during chronic treatment with alprazolam associated with enhanced cognitive performance. <i>Psychopharmacology</i> , 2005, 182, 414-419.	3.1	9
184	Role of the nuclear receptor PXR in acetaminophen hepatotoxicity. <i>Drug Metabolism and Disposition</i> , 2005, 33, 1827-36.	3.3	34
185	ATAZANAVIR: EFFECTS ON P-GLYCOPROTEIN TRANSPORT AND CYP3A METABOLISM IN VITRO. <i>Drug Metabolism and Disposition</i> , 2005, 33, 764-770.	3.3	137
186	UDP Glucuronosyltransferase (UGT) 1A6 Pharmacogenetics: I. Identification of Polymorphisms in the 5' Regulatory and Exon 1 Regions, and Association with Human Liver UGT1A6 Gene Expression and Glucuronidation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2005, 313, 1331-1339.	2.5	52
187	Interaction of Warfarin With Drugs, Natural Substances, and Foods. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 127-132.	2.0	162
188	Clonazepam Pharmacokinetics: Comparison of Subcutaneous Microsphere Injection With Multiple-Dose Oral Administration. <i>Journal of Clinical Pharmacology</i> , 2005, 45, 1288-1293.	2.0	12
189	The Influence of Age and Sex on the Clearance of Cytochrome P450 3A Substrates. <i>Clinical Pharmacokinetics</i> , 2005, 44, 33-60.	3.5	250
190	Effect of Age on in Vitro Triazolam Biotransformation in Male Human Liver Microsomes. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 308, 874-879.	2.5	27
191	INTERACTION OF TRIAZOLAM AND KETOCONAZOLE IN P-GLYCOPROTEIN-DEFICIENT MICE. <i>Drug Metabolism and Disposition</i> , 2004, 32, 800-804.	3.3	34
192	EVALUATION OF 5-HYDROXYTRYPTOPHOL AND OTHER ENDOGENOUS SEROTONIN (5-HYDROXYTRYPTAMINE) ANALOGS AS SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 1A6. <i>Drug Metabolism and Disposition</i> , 2004, 32, 862-869.	3.3	48
193	The Effect of Age on P-Glycoprotein Expression and Function in the Fischer-344 Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 730-736.	2.5	34
194	UDP-Glucuronosyltransferase (UGT) 2B15 Pharmacogenetics: UGT2B15 D85Y Genotype and Gender Are Major Determinants of Oxazepam Glucuronidation by Human Liver. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 310, 656-665.	2.5	105
195	Age-Related Differences in CYP3A Expression and Activity in the Rat Liver, Intestine, and Kidney. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2004, 309, 720-729.	2.5	56
196	Role of CYP3A enzymes in the biotransformation of triazolam in rat liver. <i>Xenobiotica</i> , 2004, 34, 463-471.	1.1	3
197	LEVOTHYROXINE UP-REGULATES P-GLYCOPROTEIN INDEPENDENT OF THE PREGNANE X RECEPTOR. <i>Drug Metabolism and Disposition</i> , 2004, 32, 779-782.	3.3	46
198	Interdose Elevation in Plasma Cortisol During Chronic Treatment with Alprazolam but not Lorazepam in the Elderly. <i>Neuropsychopharmacology</i> , 2004, 29, 605-611.	5.4	14

#	ARTICLE	IF	CITATIONS
199	Effects of Acute Lorazepam Administration on Aminergic Activity in Normal Elderly Subjects: Relationship to Performance Effects and Apolipoprotein Genotype. <i>Neurochemical Research</i> , 2004, 29, 1391-1398.	3.3	6
200	Baseline Plasma GABA: Its Relationship to the Adverse Effects of Acute Lorazepam Administration on Cognition in the Elderly. <i>Neurochemical Research</i> , 2004, 29, 2311-2315.	3.3	2
201	Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A. <i>Biopharmaceutics and Drug Disposition</i> , 2004, 25, 283-289.	1.9	28
202	Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 76, 467-479.	4.7	82
203	Kinetics and EEG Effects of Midazolam during and after 1-Minute, 1-Hour, and 3-Hour Intravenous Infusions. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 605-611.	2.0	25
204	Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats. <i>Xenobiotica</i> , 2004, 34, 133-150.	1.1	72
205	Intramuscular Haloperidol or Lorazepam and QT Intervals in Schizophrenia. <i>Journal of Clinical Pharmacology</i> , 2004, 44, 1173-1184.	2.0	17
206	Analysis of generic antiretroviral formulations manufactured in India. <i>Aids</i> , 2004, 18, 1482-1484.	2.2	7
207	Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 225-238.	5.7	187
208	Clinical Pharmacology and Therapeutics of Antidepressants. , 2004, , 33-117.		6
209	Rapid assessment of P-glycoprotein inhibition and induction in vitro. <i>Pharmaceutical Research</i> , 2003, 20, 1177-1183.	3.5	77
210	Validation of Serotonin (5-Hydroxytryptamine) as an in Vitro Substrate Probe for Human UDP-Glucuronosyltransferase (UGT) 1A6. <i>Drug Metabolism and Disposition</i> , 2003, 31, 133-139.	3.3	104
211	Human cytochromes mediating gepirone biotransformation at low substrate concentrations. <i>Biopharmaceutics and Drug Disposition</i> , 2003, 24, 87-94.	1.9	11
212	Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice. <i>Clinical Pharmacology and Therapeutics</i> , 2003, 74, 121-129.	4.7	161
213	Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 297-304.	2.4	89
214	Apparent Mechanism-based Inhibition of Human CYP2D6 in Vitro by Paroxetine: Comparison with Fluoxetine and Quinidine. <i>Drug Metabolism and Disposition</i> , 2003, 31, 289-293.	3.3	267
215	IN VITRO METABOLISM OF MIDAZOLAM, TRIAZOLAM, NIFEDIPINE, AND TESTOSTERONE BY HUMAN LIVER MICROSOMES AND RECOMBINANT CYTOCHROMES P450: ROLE OF CYP3A4 AND CYP3A5. <i>Drug Metabolism and Disposition</i> , 2003, 31, 938-944.	3.3	232
216	Clinically Important Drug Interactions with Zopiclone, Zolpidem and Zaleplon. <i>CNS Drugs</i> , 2003, 17, 513-532.	5.9	95

#	ARTICLE	IF	CITATIONS
217	EVALUATION OF 3- ² -AZIDO-3- ² -DEOXYTHYMIDINE, MORPHINE, AND CODEINE AS PROBE SUBSTRATES FOR UDP-GLUCURONOSYLTRANSFERASE 2B7 (UGT2B7) IN HUMAN LIVER MICROSOMES: SPECIFICITY AND INFLUENCE OF THE UGT2B7* POLYMORPHISM. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1125-1133.	3.3	237
218	THE EFFECT OF AGE ON SILDENAFIL BIOTRANSFORMATION IN RAT AND MOUSE LIVER MICROSOMES. <i>Drug Metabolism and Disposition</i> , 2003, 31, 1306-1309.	3.3	12
219	Drug Metabolism and Drug Interactions: Application and Clinical Value of In Vitro Models. <i>Current Drug Metabolism</i> , 2003, 4, 423-459.	1.2	151
220	The Safety of Over-the-Counter Drugs: Some Reflections and Unanswered Questions. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 111-112.	1.4	4
221	Short-Term Exposure to Low-Dose Ritonavir Impairs Clearance and Enhances Adverse Effects of Trazodone. <i>Journal of Clinical Pharmacology</i> , 2003, 43, 414-422.	2.0	53
222	Comparative Abuse Liability and Pharmacological Effects of Meprobamate, Triazolam, and Butabarbital. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 269-280.	1.4	25
223	Imipramine and Buspirone in Patients With Panic Disorder Who Are Discontinuing Long-term Benzodiazepine Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2003, 23, 505-508.	1.4	19
224	Lopinavir: acute exposure inhibits P-glycoprotein; extended exposure induces P-glycoprotein. <i>Aids</i> , 2003, 17, 1092-4.	2.2	29
225	In Vitro, Pharmacokinetic, and Pharmacodynamic Interactions of Ketoconazole and Midazolam in the Rat. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2002, 302, 1228-1237.	2.5	96
226	Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1257-1265.	3.3	155
227	In Vitro Biotransformation of Sildenafil (Viagra) in the Male Rat: The Role of CYP2C11. <i>Drug Metabolism and Disposition</i> , 2002, 30, 655-657.	3.3	26
228	Microsomal Protein Concentration Modifies the Apparent Inhibitory Potency of CYP3A Inhibitors. <i>Drug Metabolism and Disposition</i> , 2002, 30, 1441-1445.	3.3	89
229	Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 376-382.	2.0	37
230	Fexofenadine Transport in Caco-2 Cells: Inhibition with Verapamil and Ritonavir. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1269-1274.	2.0	80
231	Evaluation of Supermix TM as an in vitro model of human liver microsomal drug metabolism. <i>Biopharmaceutics and Drug Disposition</i> , 2002, 23, 183-190.	1.9	10
232	Effect of zolpidem on human Cytochrome P450 activity, and on transport mediated by P-glycoprotein. <i>Biopharmaceutics and Drug Disposition</i> , 2002, 23, 361-367.	1.9	29
233	Differential modulation of P-glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase inhibitors in cell culture. <i>Pharmaceutical Research</i> , 2002, 19, 1038-1045.	3.5	115
234	Limited Sampling Strategy to Predict AUC of the CYP3A Phenotyping Probe Midazolam in Adults: Application to Various Assay Techniques. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 376-382.	2.0	12

#	ARTICLE	IF	CITATIONS
235	Zolpidem Pharmacokinetic Properties in Young Females: Influence of Smoking and Oral Contraceptive Use. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 1142-1146.	2.0	19
236	Limited sampling strategy to predict AUC of the CYP3A phenotyping probe midazolam in adults: application to various assay techniques. <i>Journal of Clinical Pharmacology</i> , 2002, 42, 376-82.	2.0	18
237	P-glycoprotein Interactions of Nefazodone and Trazodone in Cell Culture. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 708-714.	2.0	36
238	A BENZODIAZEPINE MOOD EFFECT SCALE: RELIABILITY AND VALIDITY DETERMINED FOR ALCOHOL-DEPENDENT SUBJECTS AND ADULTS WITH A PARENTAL HISTORY OF ALCOHOLISM. <i>American Journal of Drug and Alcohol Abuse</i> , 2001, 27, 339-347.	2.1	6
239	Relative Contribution of CYP3A to Amitriptyline Clearance in Humans: In Vitro and In Vivo Studies. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1043-1054.	2.0	57
240	Drug Transporters Revisited. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 1-3.	1.4	9
241	Molecular and Pharmacokinetic Evaluation of Rat Hepatic and Gastrointestinal Cytochrome P450 Induction by Tamoxifen. <i>Pharmacology</i> , 2001, 63, 210-219.	2.2	14
242	Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. <i>European Journal of Clinical Pharmacology</i> , 2001, 57, 31-36.	1.9	104
243	Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1829-1837.	3.3	117
244	Saint John's wort: An in vitro analysis of P-glycoprotein induction due to extended exposure. <i>British Journal of Pharmacology</i> , 2001, 134, 1601-1608.	5.4	162
245	Pharmacodynamic and receptor binding changes during chronic lorazepam administration. <i>Pharmacology Biochemistry and Behavior</i> , 2001, 69, 1-8.	2.9	23
246	Human Drug Metabolism and the Cytochromes P450: Application and Relevance of In Vitro Models. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 1149-1179.	2.0	261
247	Inhibition of Human Cytochrome P450 Isoforms by Nonnucleoside Reverse Transcriptase Inhibitors. <i>Journal of Clinical Pharmacology</i> , 2001, 41, 85-91.	2.0	104
248	Drug Interactions With Grapefruit Juice: An Update. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 357-359.	1.4	51
249	Selective Serotonin Reuptake Inhibitor Antidepressants: Cardiovascular Complications—Sorting Through Findings. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 467-468.	1.4	7
250	Cognitive toxicity of drugs used in the elderly. <i>Dialogues in Clinical Neuroscience</i> , 2001, 3, 181-190.	3.7	8
251	Ritonavir induces P-glycoprotein expression, multidrug resistance-associated protein (MRP1) expression, and drug transporter-mediated activity in a human intestinal cell line. <i>Journal of Pharmaceutical Sciences</i> , 2001, 90, 1829-1837.	3.3	9
252	Unusually Low Clearance of Two CYP3A Substrates, Alprazolam and Trazodone, in a Volunteer Subject with Wild-Type CYP3A4 Promoter Region. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 200-204.	2.0	5

#	ARTICLE	IF	CITATIONS
253	Kinetics and dynamics of lorazepam during and after continuous intravenous infusion. <i>Critical Care Medicine</i> , 2000, 28, 2750-2757.	0.9	37
254	The Influence of the Menstrual Cycle on Triazolam and Indocyanine Green Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 2000, 40, 739-744.	2.0	12
255	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 129-136.	2.1	65
256	Methodologies to study the induction of rat hepatic and intestinal cytochrome P450 3A at the mRNA, protein, and catalytic activity level. <i>Journal of Pharmacological and Toxicological Methods</i> , 2000, 43, 41-54.	0.7	39
257	Alprazolam-ritonavir interaction: Implications for product labeling. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 335-341.	4.7	114
258	Differential Impairment of Triazolam and Zolpidem Clearance by Ritonavir. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2000, 24, 129-136.	2.1	67
259	Imipramine and Bupropion in Treatment of Patients With Generalized Anxiety Disorder Who Are Discontinuing Long-Term Benzodiazepine Therapy. <i>American Journal of Psychiatry</i> , 2000, 157, 1973-1979.	7.2	75
260	In vitro metabolism of trazodone by CYP3A: inhibition by ketoconazole and human immunodeficiency viral protease inhibitors. <i>Biological Psychiatry</i> , 2000, 47, 655-661.	1.3	53
261	Effects of the Antifungal Agents on Oxidative Drug Metabolism. <i>Clinical Pharmacokinetics</i> , 2000, 38, 111-180.	3.5	471
262	Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. <i>Aids</i> , 2000, 14, 1287.	2.2	76
263	Drug Transporters in Psychopharmacology-Are They Important?. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 291-294.	1.4	10
264	Differences in Pharmacodynamics but Not Pharmacokinetics Between Subjects With Panic Disorder and Healthy Subjects After Treatment With a Single Dose of Alprazolam. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 338-346.	1.4	15
265	More on Oral Contraceptives, Drug Interactions, Herbal Medicines, and Hormone Replacement Therapy. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 397-398.	1.4	7
266	Lack of Effect of Sertraline on the Pharmacokinetics of Alprazolam. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 585-586.	1.4	8
267	A Comparative Pharmacokinetic and Dynamic Evaluation of Alprazolam Sustained-Release, Bromazepam, and Lorazepam. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 628-635.	1.4	18
268	Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 355-369.	5.7	162
269	Comparative kinetics and response to the benzodiazepine agonists triazolam and zolpidem: evaluation of sex-dependent differences. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2000, 293, 435-443.	2.5	85
270	In situ hybridization histochemistry as a method to assess GABA _A receptor subunit mRNA expression following chronic alprazolam administration. <i>Journal of Psychopharmacology</i> , 1999, 13, 211-218.	4.0	8

#	ARTICLE	IF	CITATIONS
271	Zolpidem metabolism in vitro : responsible cytochromes, chemical inhibitors, and in vivo correlations. British Journal of Clinical Pharmacology, 1999, 48, 89-97.	2.4	136
272	Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole. Clinical Pharmacology and Therapeutics, 1999, 66, 461-471.	4.7	234
273	Nefazodone, meta-chlorophenylpiperazine, and their metabolites in vitro: cytochromes mediating transformation, and P450-3A4 inhibitory actions. Psychopharmacology, 1999, 145, 113-122.	3.1	75
274	Unchanged cytochrome P450 3A (CYP3A) expression and metabolism of midazolam, triazolam, and dexamethasone in mdr(âˆ™/âˆ™) mouse liver microsomes. Biochemical Pharmacology, 1999, 57, 1227-1232.	4.4	27
275	Lorazepam Attenuates the Behavioral Effects of Dizocilpine. Pharmacology Biochemistry and Behavior, 1999, 62, 103-110.	2.9	10
276	O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells Effect of Metabolic Inhibitors and SSRI Antidepressants. Neuropsychopharmacology, 1999, 20, 480-490.	5.4	145
277	Inhibition of human cytochrome P450 isoforms in vitro by zafirlukast. Biopharmaceutics and Drug Disposition, 1999, 20, 385-388.	1.9	27
278	Pharmacokinetics and electroencephalographic effects of ketoconazole in the rat. , 1999, 20, 49-52.		6
279	Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects. Biological Psychiatry, 1999, 46, 839-849.	1.3	80
280	EXTRAPOLATING IN VITRO DATA ON DRUG METABOLISM TO IN VIVO PHARMACOKINETICS: EVALUATION OF THE PHARMACOKINETIC INTERACTION BETWEEN AMITRIPTYLINE AND FLUOXETINE. Drug Metabolism Reviews, 1999, 31, 545-560.	3.6	34
281	Nortriptyline E-10-Hydroxylation in Vitro Is Mediated by Human CYP2D6 (High Affinity) and CYP3A4 (Low) Tj ETQq1 1 0.784314 rgBT Pharmacology, 1999, 39, 567-577.	2.0	80
282	Population Pharmacokinetics of Methylphenidate in Children with Attention-Deficit Hyperactivity Disorder. Journal of Clinical Pharmacology, 1999, 39, 775-785.	2.0	46
283	Mass Units or Molar Units for Drug Concentration?. Journal of Clinical Psychopharmacology, 1999, 19, 1-2.	1.4	1
284	The Reappearance of a Monamine Oxidase Inhibitor (Isocarboxazid). Journal of Clinical Psychopharmacology, 1999, 19, 105-106.	1.4	14
285	Extensive Impairment of Triazolam and Alprazolam Clearance by Short-Term Low-Dose Ritonavir. Journal of Clinical Psychopharmacology, 1999, 19, 293-296.	1.4	58
286	Human Cytochromes and Some Newer Antidepressants: Kinetics, Metabolism, and Drug Interactions. Journal of Clinical Psychopharmacology, 1999, 19, 23S-35S.	1.4	82
287	Human Cytochromes Mediating Sertraline Biotransformation: Seeking Attribution. Journal of Clinical Psychopharmacology, 1999, 19, 489-493.	1.4	29
288	Kinetic and dynamic interaction study of zolpidem with ketoconazole, itraconazole, and fluconazole*. Clinical Pharmacology and Therapeutics, 1998, 64, 661-671.	4.7	80

#	ARTICLE	IF	CITATIONS
289	Comparative kinetics and dynamics of zaleplon, zolpidem, and placebo*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 553-561.	4.7	113
290	Ketoconazole inhibition of triazolam and alprazolam clearance: Differential kinetic and dynamic consequences*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 237-247.	4.7	120
291	Inhibition of triazolam clearance by macrolide antimicrobial agents: In vitro correlates and dynamic consequences*. <i>Clinical Pharmacology and Therapeutics</i> , 1998, 64, 278-285.	4.7	90
292	Relative Quantities of Catalytically Active CYP 2C9 and 2C19 in Human Liver Microsomes: Application of the Relative Activity Factor Approach. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 845-853.	3.3	47
293	Inhibition of Desipramine Hydroxylation (Cytochrome P450-2D6) in Vitro by Quinidine and by Viral Protease Inhibitors: Relation to Drug Interactions in Vivo. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1184-1189.	3.3	73
294	Human cytochromes P450 mediating phenacetin Oâ€œdeethylation in vitro: Validation of the high affinity component as an index of CYP1A2 activity. <i>Journal of Pharmaceutical Sciences</i> , 1998, 87, 1502-1507.	3.3	64
295	Analysis of ritonavir in plasma/serum and tissues by high-performance liquid chromatography. <i>Journal of Pharmacological and Toxicological Methods</i> , 1998, 40, 235-239.	0.7	22
296	In Vitro Approaches to Predicting Drug Interactions In Vivo. <i>Biochemical Pharmacology</i> , 1998, 55, 113-122.	4.4	188
297	Pharmacokinetics and Pharmacodynamics of Diphenhydramine 25 mg in Young and Elderly Volunteers. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 603-609.	2.0	44
298	Five Distinct Human Cytochromes Mediate Amitriptyline Nâ€œDemethylation <i>In Vitro</i>: Dominance of CYP 2C19 and 3A4. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 112-121.	2.0	138
299	Singleâ€œDose Pharmacokinetics and Pharmacodynamics of Alprazolam in Elderly and Young Subjects. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 14-21.	2.0	27
300	Protease Inhibitors as Inhibitors of Human Cytochromes P450: High Risk Associated with Ritonavir. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 106-111.	2.0	228
301	The Maturation of Clinical Pharmacology: Recognizing the Contributions of Dr. Louis Lasagna. <i>Journal of Clinical Pharmacology</i> , 1998, 38, 572-574.	2.0	6
302	Clozapine and Fluvoxamine, a Curious Complexity. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 101-102.	1.4	17
303	Nefazodone in Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 145-153.	1.4	16
304	ApoE-epsilon4 Allele and Susceptibility to Drug-Induced Memory Impairment in the Elderly. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 179-181.	1.4	10
305	Conflicts of Interest, Redundant Publication, and Identification of Authorship. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 183-184.	1.4	5
306	Alprazolam Is Another Substrate for Human Cytochrome P450-3A Isoforms. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 256.	1.4	39

#	ARTICLE	IF	CITATIONS
307	Epiphenomenal, Causal, or Correlational-More on the Mechanism(s) of Action of Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 265-267.	1.4	3
308	Appetite Suppressant Drugs as Inhibitors of Human Cytochromes P450. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 338-341.	1.4	12
309	Potassium, Antipsychotic Agents, Arrhythmias, and Sudden Death. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 427-428.	1.4	16
310	Differential Effect of Central versus Parenteral Administration of Morphine Sulfate on Regional Concentrations of Reduced Glutathione in Rat Brain. <i>Pharmacology</i> , 1997, 54, 92-97.	2.2	20
311	Influence of Oral Contraceptive Use and Cigarette Smoking, Alone and Together, on Antipyrine Pharmacokinetics. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 437-441.	2.0	12
312	The NMDA Receptor Competitive Antagonist CPP Modulates Benzodiazepine Tolerance and Discontinuation. <i>Pharmacology</i> , 1997, 55, 217-227.	2.2	31
313	Alterations in Pharmacodynamics of Anxiolytics in Abstinent Alcoholic Men: Subjective Responses, Abuse Liability, and Electroencephalographic Effects of Alprazolam, Diazepam, and Buspirone. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 64-73.	2.0	25
314	Biotransformation of Mestranol to Ethinyl Estradiol In Vitro: The Role of Cytochrome P450 2C9 and Metabolic Inhibitors. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 193-200.	2.0	34
315	Molecular basis for deficient acetaminophen glucuronidation in cats. <i>Biochemical Pharmacology</i> , 1997, 53, 1041-1047.	4.4	170
316	Dose-Dependent Pharmacokinetics and Psychomotor Effects of Caffeine in Humans. <i>Journal of Clinical Pharmacology</i> , 1997, 37, 693-703.	2.0	309
317	Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. <i>Biological Psychiatry</i> , 1997, 41, 377-380.	1.3	25
318	Human cytochromes mediating N-demethylation of fluoxetine in vitro. <i>Psychopharmacology</i> , 1997, 132, 402-407.	3.1	77
319	Chronic alcohol abuse and the acute sedative and neurophysiologic effects of midazolam. <i>Psychopharmacology</i> , 1997, 133, 293-299.	3.1	14
320	Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. <i>British Journal of Clinical Pharmacology</i> , 1997, 44, 495-498.	2.4	90
321	ALPRAZOLAM HYDROXYLATION BY MOUSE LIVER MICROSOMES IN VITRO: THE EFFECT OF AGE AND PHENOBARBITAL INDUCTION. , 1997, 18, 139-149.		6
322	Biotransformation of Chlorzoxazone by Hepatic Microsomes from Humans and Ten Other Mammalian Species. , 1997, 18, 213-226.		105
323	Metabolism of Dextromethorphan in vitro: Involvement of Cytochromes P450 2D6 AND 3A3/4, with a Possible Role of 2E1. <i>Biopharmaceutics and Drug Disposition</i> , 1997, 18, 227-240.	1.9	73
324	Newer Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 1-3.	1.4	15

#	ARTICLE	IF	CITATIONS
325	Newer Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 75-77.	1.4	4
326	Fruit Juices and Pharmacology. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 245-246.	1.4	5
327	Desipramine Pharmacokinetics When Coadministered With Paroxetine or Sertraline in Extensive Metabolizers. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 284-291.	1.4	105
328	Question the Experts. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 331.	1.4	10
329	Hypnotic Effects of Low Doses of Quazepam in Older Insomniacs. <i>Journal of Clinical Psychopharmacology</i> , 1997, 17, 401-406.	1.4	20
330	Inhibition of Human Cytochrome P450 CYP3A Isoforms by Fluoxetine and Norfluoxetine: <i>In Vitro</i> and <i>In Vivo</i> Studies. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 792-798.	2.0	51
331	Pharmacokinetic-Pharmacodynamic Relationships For Benzodiazepines. <i>Clinical Pharmacokinetics</i> , 1996, 30, 52-76.	3.5	81
332	Midazolam Hydroxylation by Human Liver Microsomes <i>In Vitro</i> : Inhibition by Fluoxetine, Norfluoxetine, and by Azole Antifungal Agents. <i>Journal of Clinical Pharmacology</i> , 1996, 36, 783-791.	2.0	185
333	Phenacetin O -deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine. <i>Psychopharmacology</i> , 1996, 128, 398-407.	3.1	102
334	Effect of Diazepam on Plasma gamma-Aminobutyric Acid in Sons of Alcoholic Fathers. <i>Alcoholism: Clinical and Experimental Research</i> , 1996, 20, 343-347.	2.4	11
335	Inhibition of cytochrome P450 by nefazodone in vitro : studies of dextromethorphan O -and N -demethylation. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 339-343.	2.4	44
336	Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N -demethylation. <i>British Journal of Clinical Pharmacology</i> , 1996, 41, 593-604.	2.4	35
337	Influence of Polyethylene Glycol and Acetone on the in Vitro Biotransformation of Tamoxifen and Alprazolam by Human Liver Microsomes. <i>Journal of Pharmaceutical Sciences</i> , 1996, 85, 1180-1185.	3.3	16
338	Characterization of Six in vitro Reactions Mediated by Human Cytochrome P450: Application to the Testing of Cytochrome P450-Directed Antibodies. <i>Pharmacology</i> , 1996, 52, 125-134.	2.2	41
339	Twice May Be Too Many. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 1-2.	1.4	12
340	Inhibition of Terfenadine Metabolism In Vitro by Azole Antifungal Agents and by Selective Serotonin Reuptake Inhibitor Antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 104-112.	1.4	78
341	The Clinician and Drug Interactions-An Update. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 197-201.	1.4	46
342	Treatment, Discontinuation, and Psychomotor Effects of Diazepam in Women With Generalized Anxiety Disorder. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 202-207.	1.4	11

#	ARTICLE	IF	CITATIONS
343	Relationship of In Vitro Data on Drug Metabolism to In Vivo Pharmacokinetics and Drug Interactions. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 267-272.	1.4	44
344	Protease Inhibitors and Drug Interactions-An Alert. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 343-344.	1.4	6
345	The Importance of Presystemic Extraction in Clinical Psychopharmacology. <i>Journal of Clinical Psychopharmacology</i> , 1996, 16, 417-419.	1.4	7
346	Effects of diphenhydramine on human eye movements. <i>Psychopharmacology</i> , 1995, 118, 280-286.	3.1	16
347	Benzodiazepine Sensitivity in Panic Disorder: Effects of Chronic Alprazolam Treatment. <i>Neuropsychopharmacology</i> , 1995, 12, 147-157.	5.4	52
348	Metabolism of Drugs by Cytochrome P450 3A Isoforms. <i>Clinical Pharmacokinetics</i> , 1995, 29, 33-44.	3.5	107
349	More on Drugs and Pregnancy. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 1-2.	1.4	5
350	Inhibition of Alprazolam and Desipramine Hydroxylation In Vitro by Paroxetine and Fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 125-131.	1.4	166
351	The Life of Milton Greenblatt. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 155-159.	1.4	1
352	Eye Movement Effects of Diazepam in Sons of Alcoholic Fathers and Male Control Subjects. <i>Alcoholism: Clinical and Experimental Research</i> , 1994, 18, 324-332.	2.4	40
353	Distinguishing a benzodiazepine agonist (triazolam) from a nonagonist anxiolytic (buspirone) by electroencephalography: Kinetic-dynamic studies. <i>Clinical Pharmacology and Therapeutics</i> , 1994, 56, 100-111.	4.7	55
354	In Vitro Prediction of the Terfenadine-Ketoconazole Pharmacokinetic Interaction. <i>Journal of Clinical Pharmacology</i> , 1994, 34, 1222-1227.	2.0	99
355	Inhibition of acetaminophen and lorazepam glucuronidation in vitro by probenecid. <i>Biopharmaceutics and Drug Disposition</i> , 1993, 14, 119-130.	1.9	26
356	Cognitive effects of Î²-adrenergic antagonists after single doses: Pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1993, 53, 577-584.	4.7	33
357	Benzodiazepine pharmacodynamics: utility of eye movement measures. <i>Psychopharmacology</i> , 1993, 110, 85-91.	3.1	42
358	Chronic benzodiazepine administration. <i>Psychopharmacology</i> , 1993, 111, 91-95.	3.1	15
359	Clinical Pharmacokinetics of Antidepressants in the Elderly. <i>Clinical Pharmacokinetics</i> , 1993, 24, 141-160.	3.5	41
360	Clinical Pharmacokinetics of Alprazolam. <i>Clinical Pharmacokinetics</i> , 1993, 24, 453-471.	3.5	327

#	ARTICLE	IF	CITATIONS
361	Personality and benzodiazepine sensitivity in anxious patients and control subjects. <i>Psychiatry Research</i> , 1993, 47, 151-162.	3.3	44
362	Presystemic Extraction: Mechanisms and Consequences. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 650-656.	2.0	16
363	Use of Benzodiazepines in Anxiety Disorders. <i>New England Journal of Medicine</i> , 1993, 328, 1398-1405.	27.0	305
364	Chronic Benzodiazepine Administration XI Concurrent Administration of PK11195 Attenuates Lorazepam Discontinuation Effects. <i>Neuropsychopharmacology</i> , 1993, 8, 267-273.	5.4	15
365	Alprazolam Metabolism in vitro: Studies of Human, Monkey, Mouse, and Rat Liver Microsomes. <i>Pharmacology</i> , 1993, 47, 268-276.	2.2	91
366	Plasma Alprazolam Concentrations. <i>Archives of General Psychiatry</i> , 1993, 50, 715.	12.3	35
367	Norcocaine and N-Hydroxynorcocaine Formation in Human Liver Microsomes: Role of Cytochrome P-450 3A4. <i>Pharmacology</i> , 1993, 46, 294-300.	2.2	65
368	Kinetic-Dynamic Modeling in Clinical. <i>Journal of Clinical Psychopharmacology</i> , 1993, 13, 231-234.	1.4	12
369	Antipyrine Kinetics in Patients with Primary Biliary Cirrhosis. <i>Journal of Clinical Pharmacology</i> , 1993, 33, 75-78.	2.0	6
370	Response to Diazepam in Sons of Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1992, 16, 1057-1063.	2.4	33
371	Clinical Therapeutic Conference: Pharmacokinetic Principles in Clinical Medicine. <i>Journal of Clinical Pharmacology</i> , 1992, 32, 118-123.	2.0	2
372	A Possible New Approach to the Treatment of. <i>Journal of Clinical Psychopharmacology</i> , 1992, 12, 155.	1.4	0
373	Benzodiazepine receptor binding of nonbenzodiazepines in vivo: Alpidem, zolpidem and zopiclone. <i>Brain Research Bulletin</i> , 1992, 29, 905-908.	3.0	40
374	Pharmacokinetics and pharmacodynamics of oral diazepam: Effect of dose, plasma concentration, and time. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 139-150.	4.7	88
375	Fluoxetine impairs clearance of alprazolam but not of clonazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1992, 52, 479-486.	4.7	142
376	Benzodiazepine receptor binding of benzodiazepine hypnotics: Receptor and ligand specificity. <i>Pharmacology Biochemistry and Behavior</i> , 1992, 43, 413-416.	2.9	20
377	Effect of acute and chronic benzodiazepines on plasma GABA in anxious patients and controls. <i>Psychopharmacology</i> , 1992, 109, 153-156.	3.1	20
378	Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly. <i>Clinical Pharmacokinetics</i> , 1991, 21, 165-177.	3.5	158

#	ARTICLE	IF	CITATIONS
379	Clinical Pharmacokinetics of Anxiolytics and Hypnotics in the Elderly. <i>Clinical Pharmacokinetics</i> , 1991, 21, 262-273.	3.5	116
380	Accelerated benzodiazepine receptor recovery after lorazepam discontinuation. <i>FASEB Journal</i> , 1991, 5, 93-97.	0.5	5
381	Benzodiazepine Receptor Binding Response to Acute and Chronic Stress Is Increased in Aging Animals. <i>Pharmacology</i> , 1991, 42, 181-187.	2.2	7
382	Contribution of the Gastrointestinal Tract to Lorazepam Conjugation and Clonazepam Nitroreduction. <i>Pharmacology</i> , 1991, 42, 36-48.	2.2	5
383	Appropriate Use and Regulatory Control of Benzodiazepines. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 781-784.	2.0	39
384	Differential Side Effect Profile of Triazolam Versus Flurazepam in Elderly Patients Undergoing Rehabilitation Therapy. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 168-173.	2.0	12
385	Validity of Self-Reports of Caffeine Use. <i>Journal of Clinical Pharmacology</i> , 1991, 31, 677-680.	2.0	18
386	Prenatal benzodiazepine administration. II. Lorazepam exposure is associated with decreases in [35S]TBPS binding but not benzodiazepine binding. <i>Pharmacology Biochemistry and Behavior</i> , 1991, 40, 429-432.	2.9	6
387	Modification of γ -Aminobutyric Acid Receptor Binding and Function by N-Ethoxycarbonyl-2-Ethoxy-1,2-Dihydroquinoline In Vitro and In Vivo: Effects of Aging. <i>Journal of Neurochemistry</i> , 1991, 56, 1241-1247.	3.9	20
388	Pharmacokinetic and dynamic correlates of intravenous alprazolam challenge. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 656-662.	4.7	2
389	Chronic benzodiazepine administration. <i>Psychopharmacology</i> , 1991, 104, 225-230.	3.1	45
390	Comparative pharmacokinetics of alprazolam and lorazepam in humans and in African Green Monkeys. <i>Psychopharmacology</i> , 1991, 104, 103-105.	3.1	21
391	Sensitivity to Triazolam in the Elderly. <i>New England Journal of Medicine</i> , 1991, 324, 1691-1698.	27.0	262
392	Differential Effect of Cigarette Smoking on Antipyrine Oxidation versus Acetaminophen Conjugation. <i>Pharmacology</i> , 1990, 40, 77-84.	2.2	16
393	Validity of a Two-Point Acetaminophen Pharmacokinetic Study. <i>Therapeutic Drug Monitoring</i> , 1990, 12, 35-39.	2.0	4
394	Lithium and the Newborn Heart. <i>Journal of Clinical Psychopharmacology</i> , 1990, 10, 311.	1.4	3
395	The Neuropsychiatric Effects of Aspartame in Normal Volunteers. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 454-460.	2.0	25
396	New Pharmacokinetic Methods III. Two Simple Tests for "Deep Pool Effect". <i>Journal of Clinical Pharmacology</i> , 1990, 30, 680-685.	2.0	9

#	ARTICLE	IF	CITATIONS
397	Gas chromatographic analysis of alprazolam in plasma: replicability, stability and specificity. <i>Biomedical Applications</i> , 1990, 534, 202-207.	1.7	21
398	Benzodiazepine concentrations in brain directly reflect receptor occupancy: studies of diazepam, lorazepam, and oxazepam. <i>Psychopharmacology</i> , 1990, 102, 373-378.	3.1	73
399	Separate and combined effects of caffeine and alprazolam on motor activity and benzodiazepine receptor binding in vivo. <i>Psychopharmacology</i> , 1990, 101, 539-544.	3.1	13
400	Chronic morphine administration augments benzodiazepine binding and GABAA receptor function. <i>Psychopharmacology</i> , 1990, 101, 545-549.	3.1	30
401	Diphenhydramine kinetics following intravenous, oral, and sublingual dimenhydrinate administration. <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 185-189.	1.9	19
402	Oxidative versus conjugative biotransformation of temazepam. <i>Biopharmaceutics and Drug Disposition</i> , 1990, 11, 499-506.	1.9	32
403	Reduced Systemic Absorption of Intrabronchial Lidocaine by High-Frequency Nebulization. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 795-797.	2.0	8
404	New Pharmacokinetic Methods: I Estimation of Mean Serum Concentration From Trough Serum Concentration. <i>Journal of Clinical Pharmacology</i> , 1990, 30, 482-488.	2.0	2
405	Influence of vitamin E supplementation on antipyryng clearance in the cebus monkey. <i>Nutrition Research</i> , 1990, 10, 1045-1051.	2.9	3
406	Augmentation of GABAA receptor function by chronic exposure to GABA-neutral and GABA-negative benzodiazepine ligands in cultured cortical neurons. <i>Biochemical Pharmacology</i> , 1990, 40, 1337-1344.	4.4	13
407	Differential effects of chronic lorazepam and alprazolam on benzodiazepine binding and GABA _A receptor function. <i>British Journal of Pharmacology</i> , 1990, 101, 839-842.	5.4	23
408	Caffeine-induced behavioural stimulation is dose- and concentration-dependent. <i>British Journal of Pharmacology</i> , 1990, 100, 435-440.	5.4	28
409	Doxylamine and Diphenhydramine Pharmacokinetics in Women on Low-Dose Estrogen Oral Contraceptives. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 257-260.	2.0	19
410	Pharmacokinetic Determinants of Dynamic Differences Among Three Benzodiazepine Hypnotics. <i>Archives of General Psychiatry</i> , 1989, 46, 326.	12.3	85
411	Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. <i>European Journal of Pharmacology</i> , 1989, 172, 453-459.	2.6	48
412	Bioequivalence of a generic brand of diazepam. <i>Biopharmaceutics and Drug Disposition</i> , 1989, 10, 597-605.	1.9	14
413	Pharmacokinetic and electroencephalographic study of intravenous diazepam, midazolam, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1989, 45, 356-365.	4.7	169
414	Therapeutic serum lidocaine and metabolite concentrations in patients undergoing electrophysiologic study after discontinuation of intravenous lidocaine infusion. <i>American Heart Journal</i> , 1989, 117, 1060-1064.	2.7	18

#	ARTICLE	IF	CITATIONS
415	Chronic benzodiazepine administration. <i>Biochemical Pharmacology</i> , 1989, 38, 3773-3777.	4.4	55
416	Lorazepam discontinuation promotes α -inverse agonist TM effects of benzodiazepines. <i>British Journal of Pharmacology</i> , 1989, 98, 451-454.	5.4	20
417	Lack of Effect of Influenza Vaccine on the Pharmacokinetics of Antipyrine, Alprazolam, Paracetamol (Acetaminophen) and Lorazepam. <i>Clinical Pharmacokinetics</i> , 1989, 16, 180-185.	3.5	13
418	Clearance of the Antihistamine Doxylamine. <i>Clinical Pharmacokinetics</i> , 1989, 16, 312-316.	3.5	29
419	Arithmetic Versus Harmonic Mean Values of Elimination Half-Life: A Study of Triazolam. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 655-656.	2.0	4
420	Implications of Altered Drug Disposition in the Elderly: Studies of Benzodiazepines. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 866-872.	2.0	94
421	Chronic Treatment with Fluvoxamine, Clovoxamine, and Placebo: Interaction with Digoxin and Effects on Sleep and Alertness. <i>Journal of Clinical Pharmacology</i> , 1989, 29, 91-95.	2.0	22
422	A Large-Sample Study of Diazepam Pharmacokinetics. <i>Therapeutic Drug Monitoring</i> , 1989, 11, 652-657.	2.0	44
423	Age and Gender Effects on Chlordiazepoxide Kinetics: Relation to Antipyrine Disposition. <i>Pharmacology</i> , 1989, 38, 327-334.	2.2	33
424	HPLC Determination of Beta-Adrenergic Blockers in Biological Fluids. <i>Techniques and Instrumentation in Analytical Chemistry</i> , 1989, 4, 159-187.	0.0	0
425	Kinetics, brain uptake, and receptor binding characteristics of flurazepam and its metabolites. <i>Psychopharmacology</i> , 1988, 94, 386-91.	3.1	33
426	Comparative single-dose kinetics and dynamics of lorazepam, alprazolam, prazepam, and placebo. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 44, 326-334.	4.7	73
427	Lorazepam conjugation is unimpaired in burn trauma. <i>Clinical Pharmacology and Therapeutics</i> , 1988, 43, 250-255.	4.7	29
428	Differential modulation of benzodiazepine receptor binding by ethanol in LS and SS mice. <i>Pharmacology Biochemistry and Behavior</i> , 1988, 29, 471-477.	2.9	19
429	Low-dose alprazolam augments motor activity in mice. <i>Pharmacology Biochemistry and Behavior</i> , 1988, 30, 511-513.	2.9	24
430	Modulation of benzodiazepine receptor binding in mouse brain by adrenalectomy and steroid replacement. <i>Brain Research</i> , 1988, 446, 314-320.	2.2	44
431	Desmethyldiazepam Pharmacokinetics: Studies Following Intravenous and Oral Desmethyldiazepam, Oral Clorazepate, and Intravenous Diazepam. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 853-859.	2.0	39
432	Suppression of norepinephrine appearance rate in plasma by diazepam in humans. <i>Life Sciences</i> , 1988, 43, 1615-1623.	4.3	24

#	ARTICLE	IF	CITATIONS
433	Benzodiazepine binding sites on PC12 cells: Modulation by nerve growth factor and forskolin. <i>Neuroscience Letters</i> , 1988, 89, 342-348.	2.1	6
434	Antipyrine Absorption and Disposition in the Elderly. <i>Pharmacology</i> , 1988, 36, 125-133.	2.2	31
435	Antipyrine Pharmacokinetics in Women Receiving Conjugated Estrogens. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 463-466.	2.0	8
436	Alprazolam Pharmacokinetics in Women on Low-Dose Oral Contraceptives. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 454-457.	2.0	26
437	Metronidazole Impairs Clearance of Phenytoin but Not of Alprazolam or Lorazepam. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 240-245.	2.0	30
438	Pharmacodynamic Comparison of β -Blockers with Propranolol, Metoprolol, and Placebo. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 1101-1105.	2.0	0
439	Triazolam Kinetics: Interaction with Cimetidine, Propranolol, and the Combination. <i>Journal of Clinical Pharmacology</i> , 1988, 28, 228-233.	2.0	19
440	Pharmacokinetics and CSF Entry of Flurazepam in Dogs. <i>Pharmacology</i> , 1988, 36, 166-171.	2.2	4
441	High-Affinity Benzodiazepine Binding Sites on Rat Peritoneal Mast Cells and RBL-1 Cells: Binding Characteristics and Effects on Granule Secretion. <i>Pharmacology</i> , 1988, 36, 52-60.	2.2	17
442	Effect of Gradual Withdrawal on the Rebound Sleep Disorder after Discontinuation of Triazolam. <i>New England Journal of Medicine</i> , 1987, 317, 722-728.	27.0	92
443	Measurement of Clonazepam by Electron-Capture Gas-Liquid Chromatography with Application to Single-Dose Pharmacokinetics. <i>Journal of Analytical Toxicology</i> , 1987, 11, 55-57.	2.8	14
444	Estimation of the Elimination Half-Life of a Drug at Any Serum Concentration When the K_m and V_{max} of the Drug Are Known: Calculations and Validation With Phenytoin. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 318-320.	2.0	4
445	Antipyrine and Lidocaine Are Cleared Faster in Horses than in Humans: Acetaminophen May Be Handled Similarly. <i>Pharmacology</i> , 1987, 34, 192-200.	2.2	7
446	Drug Absorption Rate: A Critical Component of Bioequivalence Assessment in Psychopharmacology. <i>Journal of Clinical Pharmacology</i> , 1987, 27, 85-86.	2.0	7
447	Glycoconjugates as noninvasive probes of intrahepatic metabolism: I. Kinetics of label incorporation with evidence of a common precursor UDP-glucose pool for secreted glycoconjugates. <i>Metabolism: Clinical and Experimental</i> , 1987, 36, 988-994.	3.4	24
448	Rapid increase in brain benzodiazepine receptor binding following defeat stress in mice. <i>Brain Research</i> , 1987, 414, 395-400.	2.2	111
449	Pharmacokinetics of intravenous caffeine: Comparison of high-performance liquid chromatographic and gas chromatographic methods. <i>Biomedical Applications</i> , 1987, 422, 274-280.	1.7	20
450	Poor bioavailability of CGS 8216 in a water/tween vehicle following intraperitoneal injection. <i>Psychopharmacology</i> , 1987, 91, 260-1.	3.1	8

#	ARTICLE	IF	CITATIONS
451	A simplex procedure for fitting nonlinear pharmacokinetic models. <i>Computers in Biology and Medicine</i> , 1987, 17, 199-208.	7.0	30
452	Benzodiazepine receptor binding: Influence of physiologic and pharmacologic factors. <i>Biopharmaceutics and Drug Disposition</i> , 1987, 8, 103-114.	1.9	24
453	Gas chromatographic analysis of underivatized tocinide. <i>Biomedical Applications</i> , 1987, 419, 339-344.	1.7	0
454	Tyr-MIF-1 augments benzodiazepine receptor binding in vivo. <i>Pharmacology Biochemistry and Behavior</i> , 1987, 28, 521-524.	2.9	18
455	Trazodone kinetics: Effect of age, gender, and obesity. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 42, 193-200.	4.7	121
456	Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propranolol. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 562-570.	4.7	50
457	The interactions of propranolol and ketanserin. <i>Clinical Pharmacology and Therapeutics</i> , 1987, 41, 55-60.	4.7	5
458	Benzodiazepine Receptor Binding of Triazolobenzodiazepines In Vivo: Increased Receptor Number with Low-Dose Alprazolam. <i>Journal of Neurochemistry</i> , 1987, 49, 1595-1601.	3.9	33
459	Drug Disposition in Obese Humans. <i>Clinical Pharmacokinetics</i> , 1986, 11, 199-213.	3.5	171
460	Large Theophylline Requirements due to High Theophylline Clearance: Verification by the Antipyrine Test. <i>Pharmacology</i> , 1986, 32, 226-231.	2.2	11
461	Pharmacokinetic Aspects of Drug Therapy in the Elderly. <i>Therapeutic Drug Monitoring</i> , 1986, 8, 249-255.	2.0	55
462	Interaction of Diazepam With Famotidine and Cimetidine, Two H ₂ -Receptor Antagonists. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 299-303.	2.0	29
463	Cyclosporine Blood Concentrations Determined by Specific Versus Nonspecific Assay Methods. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 367-371.	2.0	9
464	Distribution. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 425-426.	2.0	2
465	Pharmacokinetics: Dose-Dependent Changes. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 463-468.	2.0	8
466	Pharmacokinetics and Clinical Effects of Alprazolam Following Single and Multiple Oral Doses in Patients With Panic Disorder. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 292-298.	2.0	47
467	Influence of age, gender, and obesity on salicylate kinetics following single doses of aspirin. <i>Arthritis and Rheumatism</i> , 1986, 29, 971-980.	6.7	45
468	Determination of ciramadol and dezocine, two new analgesics, by high-performance liquid chromatography using electrochemical detection. <i>Biomedical Applications</i> , 1986, 374, 215-220.	1.7	9

#	ARTICLE	IF	CITATIONS
469	Determination of zopiclone in plasma by liquid chromatography with application to steady-state monitoring. <i>Biomedical Applications</i> , 1986, 380, 211-215.	1.7	21
470	Sedative effects and impaired learning and recall after single oral doses of lorazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1986, 39, 526-530.	4.7	53
471	Pharmacokinetics of oxaprozin and other nonsteroidal antiinflammatory agents. <i>Seminars in Arthritis and Rheumatism</i> , 1986, 15, 18-26.	3.4	8
472	Enhanced Bioavailability of Triazolam Following Sublingual Versus Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 208-210.	2.0	45
473	More Than Skin Deep: Transdermal Drug-Delivery Systems. <i>New England Journal of Medicine</i> , 1986, 314, 1638-1639.	27.0	17
474	Pharmacokinetics of Diphenhydramine and a Demethylated Metabolite Following Intravenous And Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1986, 26, 529-533.	2.0	86
475	Kinetics of Diazepam, Midazolam, and Lorazepam in Cigarette Smokers. <i>Chest</i> , 1985, 87, 223-226.	0.8	46
476	Staggered Stable Isotope Administration Technique for Study of Drug Distribution. <i>Journal of Clinical Pharmacology</i> , 1985, 25, 309-312.	2.0	5
477	The Pharmacokineticization of Psychiatry. <i>Journal of Clinical Pharmacology</i> , 1985, 25, 239-240.	2.0	4
478	Studies With Stable Isotopes III: Pharmacokinetics of Tracer Doses of Drug. <i>Journal of Clinical Pharmacology</i> , 1985, 25, 59-63.	2.0	15
479	Effect of Ketanserin on the Kinetics of Digoxin and Digitoxin. <i>Journal of Cardiovascular Pharmacology</i> , 1985, 7, 205-207.	1.9	7
480	Studies With Stable Isotopes I: Changes in Phenytoin Pharmacokinetics and Biotransformation During Monotherapy. <i>Journal of Clinical Pharmacology</i> , 1985, 25, 43-50.	2.0	19
481	Phenelzine and the Dream Machine—Rambblings and Reflections. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 65.	1.4	69
482	The Admissibility of Positive EMIT Results as Scientific Evidence Counting Facts, Not Heads. <i>Journal of Clinical Psychopharmacology</i> , 1985, 5, 114-116.	1.4	6
483	Effect of alprazolam on digoxin kinetics and creatinine clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 595-598.	4.7	14
484	Interaction of ibuprofen with the H-2 receptor antagonists ranitidine and cimetidine. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 648-651.	4.7	34
485	Age, sex, and nitrazepam kinetics: Relation to antipyrine disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 38, 697-703.	4.7	39
486	Triazolam and ethanol interaction: Kinetic and dynamic consequences. <i>Clinical Pharmacology and Therapeutics</i> , 1985, 37, 558-562.	4.7	32

#	ARTICLE	IF	CITATIONS
487	Simplified gas chromatographic assay of underivatized nitrazepam in plasma. <i>Biomedical Applications</i> , 1985, 337, 131-135.	1.7	7
488	Ibuprofen disposition in obese individuals. <i>Arthritis and Rheumatism</i> , 1985, 28, 1117-1121.	6.7	48
489	Ibuprofen kinetics in patients with renal insufficiency who are receiving maintenance hemodialysis. <i>Arthritis and Rheumatism</i> , 1985, 28, 1430-1434.	6.7	11
490	Pharmacokinetics and bioavailability of ciramadol, a new analgesic. <i>Drug Development Research</i> , 1985, 6, 61-66.	2.9	1
491	Comment: Triazolam-Cimetidine Reaction. <i>Drug Intelligence & Clinical Pharmacy</i> , 1985, 19, 679-679.	0.4	1
492	Tissue Distribution of Diazepam and Its Metabolite Desmethyldiazepam: A Human Autopsy Study. <i>Journal of Clinical Pharmacology</i> , 1985, 25, 613-615.	2.0	20
493	Studies With Stable Isotopes II: Phenobarbital Pharmacokinetics During Monotherapy. <i>Journal of Clinical Pharmacology</i> , 1985, 25, 51-58.	2.0	29
494	Pharmacologic properties of acebutolol: Relationship of hydrophilicity to central nervous system penetration. <i>American Heart Journal</i> , 1985, 109, 1120-1125.	2.7	11
495	Quantitation by Gas Chromatography of the 1- and 4-Hydroxy Metabolites of Midazolam in Human Plasma. <i>Pharmacology</i> , 1984, 29, 158-164.	2.2	57
496	Pharmacokinetics, Central Nervous System Uptake, and Lipid Solubility of Propranolol, Acebutolol, and Sotalol. <i>Cardiology</i> , 1984, 71, 307-314.	1.4	33
497	Plasma Levels of Trazodone: Methodology and Applications. <i>Pharmacology</i> , 1984, 28, 42-46.	2.2	20
498	Comparative Single-Dose Kinetics of Oxazolam, Prazepam, and Clorazepate: Three Precursors of Desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1984, 24, 446-451.	2.0	19
499	Benzodiazepine drug-drug interactions commonly occurring in clinical practice. <i>Current Medical Research and Opinion</i> , 1984, 8, 80-93.	1.9	18
500	Clinical Importance of the Interaction of Diazepam and Cimetidine. <i>New England Journal of Medicine</i> , 1984, 310, 1639-1643.	27.0	100
501	Rapid high-performance liquid chromatographic analysis of oxaprozin, a non-steroidal anti-inflammatory agent. <i>Biomedical Applications</i> , 1984, 310, 445-449.	1.7	12
502	Imipramine disposition in users of oral contraceptive steroids. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 35, 792-797.	4.7	64
503	Propranolol interactions with diazepam, lorazepam, and alprazolam. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 36, 451-455.	4.7	40
504	Ranitidine does not impair oxidative or conjugative metabolism: Noninteraction with antipyrine, diazepam, and lorazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 35, 188-192.	4.7	36

#	ARTICLE	IF	CITATIONS
505	Trimipramine kinetics and absolute bioavailability: Use of gas-liquid chromatography with nitrogen-phosphorus detection. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 35, 348-353.	4.7	38
506	Plasma protein binding of drugs after severe burn injury. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 35, 535-539.	4.7	87
507	Simultaneous determination of lidocaine and its deethylated metabolites using gas-liquid chromatography with nitrogen-phosphorus detection. <i>Biomedical Applications</i> , 1984, 307, 200-205.	1.7	15
508	Absorption and disposition of ibuprofen in the elderly. <i>Arthritis and Rheumatism</i> , 1984, 27, 1066-1069.	6.7	67
509	Noninteraction of Temazepam and Cimetidine. <i>Journal of Pharmaceutical Sciences</i> , 1984, 73, 399-401.	3.3	17
510	Haloperidol determination in serum and cerebrospinal fluid using gas-liquid chromatography with nitrogen-phosphorus detection: Application to pharmacokinetic studies. <i>Biomedical Applications</i> , 1984, 307, 194-199.	1.7	17
511	A pharmacokinetic study of CGS-8216, a benzodiazepine receptor ligand, in the rat. <i>Psychopharmacology</i> , 1984, 84, 420-422.	3.1	16
512	Absolute bioavailability of imipramine: Influence of food. <i>Psychopharmacology</i> , 1984, 83, 104-106.	3.1	25
513	The Influence of Obesity on the Pharmacokinetics of Oral Alprazolam and Triazolam. <i>Clinical Pharmacokinetics</i> , 1984, 9, 177-183.	3.5	84
514	Effect of cimetidine on digoxin kinetics and creatinine clearance. <i>American Heart Journal</i> , 1984, 107, 170-172.	2.7	19
515	Lidocaine disposition in obesity. <i>American Journal of Cardiology</i> , 1984, 53, 1183-1186.	1.6	73
516	Pharmacokinetic studies on Ro 15-1788, a benzodiazepine receptor ligand, in the brain of the rat. <i>Brain Research</i> , 1984, 290, 183-186.	2.2	91
517	Interaction of Cimetidine with Oxazepam, Lorazepam, and Flurazepam. <i>Journal of Clinical Pharmacology</i> , 1984, 24, 187-193.	2.0	23
518	Some Biochemical Correlates of Panic Attacks with Agoraphobia and Their Response to a New Treatment. <i>Journal of Clinical Psychopharmacology</i> , 1984, 4, 66-75.	1.4	142
519	Is Temazepam an Accumulating Hypnotic?. <i>Journal of Clinical Pharmacology</i> , 1984, 24, 58-64.	2.0	13
520	Evaluation of the Hypothalamic-Pituitary Effects of Digoxin. <i>Journal of Clinical Pharmacology</i> , 1984, 24, 474-479.	2.0	6
521	Absolute Bioavailability and Effect of Food and Antacid on Diazepam Absorption from a Slow-Release Preparation. <i>Journal of Clinical Pharmacology</i> , 1984, 24, 255-263.	2.0	16
522	Pharmacokinetic Noninteraction of Triazolam and Ethanol. <i>Journal of Clinical Psychopharmacology</i> , 1984, 4, 106-107.	1.4	18

#	ARTICLE	IF	CITATIONS
523	Differential Effects of Isoniazid and Oral Contraceptive Steroids on Antipyrine Oxidation and Acetaminophen Conjugation. <i>Pharmacology</i> , 1984, 28, 188-195.	2.2	18
524	Effect of Age, Gender, and Obesity on Midazolam Kinetics. <i>Anesthesiology</i> , 1984, 61, 27-35.	2.5	512
525	Repeated diazepam dosing in cirrhotic patients: Cumulation and sedation. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 33, 471-476.	4.7	50
526	Lorazepam and oxazepam kinetics in women on low-dose oral contraceptives. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 33, 628-632.	4.7	51
527	Improved liquid chromatographic analysis of phenytoin and salicylate using radial compression separation. <i>Biomedical Applications</i> , 1983, 275, 450-457.	1.7	19
528	Methods for the determination of lorazepam and chlordiazepoxide and metabolites in brain tissue. <i>Biomedical Applications</i> , 1983, 277, 201-208.	1.7	26
529	Halazepam as a precursor of desmethyldiazepam: Quantitation by electron-capture gas-liquid chromatography. <i>Psychopharmacology</i> , 1983, 80, 178-180.	3.1	9
530	Interaction of cimetidine with the triazolobenzodiazepines alprazolam and triazolam. <i>Psychopharmacology</i> , 1983, 80, 275-278.	3.1	75
531	Diphenhydramine Determination in Human Plasma by Gas-Liquid Chromatography using Nitrogen-Phosphorus Detection: Application to Single Low-Dose Pharmacokinetic Studies. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 941-943.	3.3	23
532	Absolute and Relative Bioavailability of Oral Acetaminophen Preparations. <i>Journal of Pharmaceutical Sciences</i> , 1983, 72, 955-958.	3.3	69
533	Benzodiazepine Kinetics: Implications for Therapeutics and Pharmacogeriatrics. <i>Drug Metabolism Reviews</i> , 1983, 14, 251-292.	3.6	107
534	Reduced Single-dose Clearance of Clobazam in Elderly Men Predicts Increased Multiple-dose Accumulation. <i>Clinical Pharmacokinetics</i> , 1983, 8, 83-94.	3.5	33
535	Clinical Pharmacokinetics of the Newer Benzodiazepines. <i>Clinical Pharmacokinetics</i> , 1983, 8, 233-252.	3.5	117
536	The behavioural effects of Lorazepam are poorly related to its concentration in the brain. <i>Life Sciences</i> , 1983, 32, 2033-2040.	4.3	25
537	Is Volume of Distribution at Steady State a Meaningful Kinetic Variable?. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 391-400.	2.0	24
538	Drug toxicity in patients receiving digoxin and quinidine. <i>American Heart Journal</i> , 1983, 105, 1025-1028.	2.7	18
539	Antipyretic analgesic drugs as models for studies of drug disposition in old age. <i>American Journal of Medicine</i> , 1983, 75, 127-132.	1.5	11
540	Alprazolam Kinetics in the Elderly. <i>Archives of General Psychiatry</i> , 1983, 40, 287.	12.3	105

#	ARTICLE	IF	CITATIONS
541	Metoprolol or Propranolol Does Not Alter the Kinetics of Procainamide. <i>Journal of Cardiovascular Pharmacology</i> , 1983, 5, 392-395.	1.9	5
542	Propranolol's Psychiatric Side Effects. <i>Journal of Clinical Psychopharmacology</i> , 1983, 3, 65.	1.4	2
543	Absolute Bioavailability of Oral and Intramuscular Diazepam. <i>Anesthesia and Analgesia</i> , 1983, 62, 1778.	2.2	91
544	Reduced Distribution and Clearance of Acetaminophen in Patients with Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 1983, 5, 697-699.	1.9	11
545	Current Status of Benzodiazepines. <i>New England Journal of Medicine</i> , 1983, 309, 410-416.	27.0	367
546	Impairment of Lidocaine Clearance in Elderly Male Subjects. <i>Journal of Cardiovascular Pharmacology</i> , 1983, 5, 1093-1096.	1.9	85
547	Dose-Independent Pharmacokinetics of Intravenous Lidocaine in Humans. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 186-188.	2.0	11
548	Prolonged Accumulation of Diazepam in Obesity. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 369-376.	2.0	75
549	Ibuprofen Does Not Impair Antipyrine Clearance. <i>Journal of Clinical Pharmacology</i> , 1983, 23, 517-522.	2.0	3
550	Cimetidine impairs nitrazepam clearance. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 227-230.	4.7	32
551	Pilot Pharmacokinetic Study of Brotizolam, a Thienodiazepine Hypnotic, Using Electron-Capture Gas-Liquid Chromatography. <i>Sleep</i> , 1983, 6, 72-76.	1.1	12
552	Determination of Ro 15-1788, a Benzodiazepine Antagonist, in Human Plasma by Gas-Liquid Chromatography with Nitrogen-Phosphorus Detection. <i>Pharmacology</i> , 1983, 26, 285-289.	2.2	13
553	Drug Disposition in Old Age. <i>New England Journal of Medicine</i> , 1982, 306, 1081-1088.	27.0	605
554	KINETICS OF HIGH-DOSE I.V. DIAZEPAM. <i>British Journal of Anaesthesia</i> , 1982, 54, 849-852.	3.4	15
555	Pharmacokinetic Equivalence of Stable ¹⁴ C- and ³ H-Labeled and Unlabeled Drugs. Phenobarbital in Man. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 309-315.	2.0	24
556	Impairment of Diazepam Metabolism by Low-Dose Estrogen-Containing Oral-Contraceptive Steroids. <i>New England Journal of Medicine</i> , 1982, 306, 791-792.	27.0	103
557	Importance of Protein Binding for the Interpretation of Serum or Plasma Drug Concentrations. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 259-263.	2.0	115
558	Physiologic Changes in Old Age: Relation to Altered Drug Disposition. <i>Journal of the American Geriatrics Society</i> , 1982, 30, S6-10.	2.6	28

#	ARTICLE	IF	CITATIONS
559	Age Does Not Alter Acetaminophen Absorption. <i>Journal of the American Geriatrics Society</i> , 1982, 30, 240-244.	2.6	47
560	Clobazam Kinetics: Intrasubject Variability and Effect of Food on Absorption. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 69-73.	2.0	43
561	Cimetidine Impairs Clearance of Antipyrine and Desmethyldiazepam in the Elderly. <i>Journal of the American Geriatrics Society</i> , 1982, 30, 684-689.	2.6	33
562	Daytime Carryover of Triazolam and Flurazepam in Elderly Insomniacs. <i>Sleep</i> , 1982, 5, 361-371.	1.1	127
563	A Clinical Study of Flurazepam. <i>Sleep</i> , 1982, 5, 350-360.	1.1	32
564	Effect of Food on Acetaminophen Absorption in Young and Elderly Subjects. <i>Journal of Clinical Pharmacology</i> , 1982, 22, 571-576.	2.0	54
565	Pharmacokinetics of Drugs in Obesity. <i>Clinical Pharmacokinetics</i> , 1982, 7, 108-124.	3.5	118
566	Disease-related Alterations in Cardiac Glycoside Disposition. <i>Clinical Pharmacokinetics</i> , 1982, 7, 434-451.	3.5	17
567	Liquid Chromatographic Determination of Chlordiazepoxide and Metabolites in Plasma. <i>Pharmacology</i> , 1982, 24, 261-266.	2.2	15
568	Automated Electron-Capture Gas Chromatographic Analysis of Flunitrazepam in Plasma. <i>Pharmacology</i> , 1982, 24, 82-87.	2.2	11
569	Diazepam absorption. <i>Digestive Diseases and Sciences</i> , 1982, 27, 225-230.	2.3	42
570	Kinetics and cardiac effects of propranolol in humans. <i>Klinische Wochenschrift</i> , 1982, 60, 521-525.	0.6	11
571	Desmethyldiazepam kinetics after intravenous, intramuscular, and oral administration of clorazepate dipotassium. <i>Klinische Wochenschrift</i> , 1982, 60, 411-415.	0.6	23
572	Pharmacokinetic Comparison of Sublingual Lorazepam with Intravenous, Intramuscular, and Oral Lorazepam. <i>Journal of Pharmaceutical Sciences</i> , 1982, 71, 248-252.	3.3	117
573	Prolongation of Drug Half-Life due to Obesity: Studies of Desmethyldiazepam (Clorazepate). <i>Journal of Pharmaceutical Sciences</i> , 1982, 71, 942-944.	3.3	51
574	Obesity, sex, and acetaminophen disposition. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 783-790.	4.7	111
575	Acetaminophen kinetics in the elderly. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 151-156.	4.7	90
576	Steady-state plasma desmethyldiazepam during long-term clorazepate use: Effect of antacids. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 31, 180-183.	4.7	10

#	ARTICLE	IF	CITATIONS
577	Digoxin disposition in obesity: Clinical pharmacokinetic investigation. American Heart Journal, 1981, 102, 740-744.	2.7	86
578	Effect of Magnesium-Aluminum Hydroxide and Kaolin-Pectin on Absorption of Digoxin from Tablets and Capsules. Journal of Clinical Pharmacology, 1981, 21, 26-30.	2.0	16
579	Clinical Pharmacokinetics of Oxazepam and Lorazepam. Clinical Pharmacokinetics, 1981, 6, 89-105.	3.5	340
580	Lorazepam. Drugs, 1981, 21, 161-200.	10.9	76
581	Alcohol Does Not Enhance Diazepam Absorption. Pharmacology, 1981, 22, 263-268.	2.2	22
582	Neuropsychiatric Sequelae of Pharmacotherapy of Cardiac Arrhythmias and Hypertension. Journal of Clinical Psychopharmacology, 1981, 1, 394-398.	1.4	6
583	Kinetics of Oxazepam and Lorazepam in Two Subjects with Gilbert Syndrome*. Journal of Clinical Psychopharmacology, 1981, 1, 400-402.	1.4	9
584	Comparative Protein Binding of Diazepam and Desmethyldiazepam*. Journal of Clinical Pharmacology, 1981, 21, 219-223.	2.0	19
585	Tricyclic Antidepressant Determination in Human Plasma by Gas-Liquid Chromatography Using Nitrogen-Phosphorous Detection: Application to Single-Dose Pharmacokinetic Studies. Pharmacology, 1981, 23, 57-63.	2.2	24
586	Impairment of Digoxin Clearance by Coadministration of Quinidine. Journal of Clinical Pharmacology, 1981, 21, 396-400.	2.0	29
587	The Specificity of the Extraction Fluorescence Assay for Serum or Plasma Quinidine. Journal of Clinical Pharmacology, 1981, 21, 333-336.	2.0	0
588	Kinetic equivalence of stable-isotope-labeled and unlabeled phenytoin. Clinical Pharmacology and Therapeutics, 1981, 29, 511-515.	4.7	30
589	Effects of desmethyldiazepam on diazepam kinetics: A study of effects of a metabolite on parent drug disposition. Clinical Pharmacology and Therapeutics, 1981, 29, 757-761.	4.7	13
590	Impairment of antipyrine metabolism by low-dose oral contraceptive steroids. Clinical Pharmacology and Therapeutics, 1981, 29, 106-110.	4.7	52
591	Effect of age and gender on disposition of temazepam. Journal of Pharmaceutical Sciences, 1981, 70, 1104-1107.	3.3	150
592	Benzodiazepine overdosage: Plasma concentrations and clinical outcome. Psychopharmacology, 1981, 73, 381-383.	3.1	40
593	Effect of age and sex on disposition of desmethyldiazepam formed from its precursor clorazepate. Psychopharmacology, 1981, 75, 193-197.	3.1	62
594	Binding of diazepam and desmethyldiazepam to plasma protein: Concentration-dependence and interactions. Psychopharmacology, 1981, 75, 380-382.	3.1	12

#	ARTICLE	IF	CITATIONS
595	Kinetics and clinical effects of flurazepam in young and elderly noninsomniacs. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 30, 475-486.	4.7	166
596	Diazepam Kinetics in Relation to Age and Sex. <i>Pharmacology</i> , 1981, 23, 24-30.	2.2	108
597	Diazepam interaction with antituberculosis drugs. <i>Clinical Pharmacology and Therapeutics</i> , 1981, 29, 671-678.	4.7	85
598	Noninteraction of Digitoxin and Quinidine. <i>New England Journal of Medicine</i> , 1980, 303, 672-674.	27.0	28
599	Entry of diazepam and its major metabolite into cerebrospinal fluid. <i>Psychopharmacology</i> , 1980, 70, 89-93.	3.1	97
600	Electron-capture GLC determination of clobazam and desmethyloclobazam in plasma. <i>Journal of Pharmaceutical Sciences</i> , 1980, 69, 1351-1352.	3.3	20
601	Desmethyldiazepam kinetics in the elderly after oral prazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 196-202.	4.7	86
602	Single- and multiple-dose kinetics of intravenous digoxin. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 28, 340-345.	4.7	19
603	Effect of food on enteral absorption of quinidine. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 188-193.	4.7	22
604	Diazepam disposition determinants. <i>Clinical Pharmacology and Therapeutics</i> , 1980, 27, 301-312.	4.7	354
605	Reduction in Lidocaine Clearance during Continuous Infusion and by Coadministration of Propranolol. <i>New England Journal of Medicine</i> , 1980, 303, 373-377.	27.0	160
606	Comparative Protein Binding of Diazepam and Desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1980, 20, 639-643.	2.0	9
607	Entry of quinidine into cerebrospinal fluid. <i>American Heart Journal</i> , 1980, 100, 341-346.	2.7	29
608	Intravenous quinidine: pharmacokinetic properties and effects on left ventricular performance in humans. <i>American Heart Journal</i> , 1980, 99, 468-475.	2.7	21
609	Clinical Pharmacokinetics of Quinidine. <i>Clinical Pharmacokinetics</i> , 1980, 5, 150-168.	3.5	111
610	Serum Digoxin Concentrations and Subjective Manifestations of Toxicity. <i>Pharmacology</i> , 1980, 20, 149-154.	2.2	11
611	Benzodiazepines: Some Aspects of Their Clinical Pharmacology. <i>Novartis Foundation Symposium</i> , 1980, , 141-155.	1.1	6
612	Clinical Importance of the Interaction of Phenytoin and Isoniazid. <i>Chest</i> , 1979, 75, 356-358.	0.8	95

#	ARTICLE	IF	CITATIONS
613	Pharmacokinetics and Bioavailability of Intravenous, Intramuscular, and Oral Lorazepam in Humans. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 57-63.	3.3	180
614	Pharmacokinetic and Clinical Implications of Quinidine Protein Binding. <i>Journal of Pharmaceutical Sciences</i> , 1979, 68, 466-470.	3.3	61
615	Single- and multiple-dose kinetics of estazolam, a triazolo benzodiazepine. <i>Psychopharmacology</i> , 1979, 66, 267-274.	3.1	36
616	Self-rated sedation and plasma concentrations of desmethyldiazepam following single doses of clorazepate. <i>Psychopharmacology</i> , 1979, 66, 289-290.	3.1	21
617	Single- and multiple-dose kinetics of oral lorazepam in humans: The predictability of accumulation. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1979, 7, 159-179.	0.6	34
618	Effect of age and Billroth gastrectomy on absorption of desmethyldiazepam from clorazepate. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 449-456.	4.7	28
619	Effects of three antibiotics on theophylline kinetics. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 36-40.	4.7	70
620	Lorazepam kinetics in the elderly. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 103-113.	4.7	143
621	Chlordiazepoxide and oxazepam disposition in cirrhosis. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 26, 240-246.	4.7	52
622	Single-Dose Kinetics of Prazepam, a Precursor of Desmethyldiazepam. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 445-450.	2.0	12
623	Clinical Effects of Chloral Hydrate in Hospitalized Medical Patients.. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 669-674.	2.0	17
624	Overdosage with Pentobarbital and Secobarbital: Assessment of Factors Related to Outcome. <i>Journal of Clinical Pharmacology</i> , 1979, 19, 758-768.	2.0	16
625	Reduced Serum Albumin Concentration in the Elderly: A Report from the Boston Collaborative Drug Surveillance Program. <i>Journal of the American Geriatrics Society</i> , 1979, 27, 20-22.	2.6	190
626	Effect of a cocktail on diazepam absorption. <i>Psychopharmacology</i> , 1978, 57, 199-203.	3.1	35
627	Analysis of lorazepam and its glucuronide metabolite by electron-capture gas-liquid chromatography. <i>Biomedical Applications</i> , 1978, 146, 311-320.	1.7	94
628	Absorption of oral tetracycline in patients with Billroth-II gastrectomy. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1978, 6, 295-303.	0.6	13
629	Determination of Desmethyldiazepam in Plasma by Electron-Capture GLC: Application to Pharmacokinetic Studies of Clorazepate. <i>Journal of Pharmaceutical Sciences</i> , 1978, 67, 427-429.	3.3	23
630	Dependence, Tolerance, and Addiction to Benzodiazepines: Clinical and Pharmacokinetic Considerations. <i>Drug Metabolism Reviews</i> , 1978, 8, 13-28.	3.6	217

#	ARTICLE	IF	CITATIONS
631	Clinical Pharmacokinetics of Chlordiazepoxide. <i>Clinical Pharmacokinetics</i> , 1978, 3, 381-394.	3.5	63
632	Drug interactions involving psychotropic drugs. <i>Psychosomatics</i> , 1978, 19, 671-681.	2.5	10
633	A reevaluation of intravenous quinidine. <i>American Heart Journal</i> , 1978, 96, 829-832.	2.7	15
634	Spirolactone. <i>American Heart Journal</i> , 1978, 96, 389-400.	2.7	67
635	Dose-independent pharmacokinetics of digoxin in humans. <i>American Heart Journal</i> , 1978, 96, 507-511.	2.7	36
636	Single and multiple dose pharmacokinetics of oral quinidine sulfate and gluconate. <i>American Journal of Cardiology</i> , 1978, 41, 770-777.	1.6	37
637	Reduced quinidine clearance in elderly persons. <i>American Journal of Cardiology</i> , 1978, 42, 481-485.	1.6	87
638	Pharmacokinetics and bioavailability of digoxin capsules, solution and tablets after single and multiple doses. <i>American Journal of Cardiology</i> , 1978, 42, 129-136.	1.6	28
639	Prazepam and Lorazepam, Two New Benzodiazepines. <i>New England Journal of Medicine</i> , 1978, 299, 1342-1344.	27.0	44
640	Short- and Long-Acting Oral Quinidine Preparations. <i>Angiology</i> , 1978, 29, 243-250.	1.8	2
641	Clinical Toxicity of Theophylline in Relation to Cigarette Smoking. <i>Chest</i> , 1978, 73, 455-459.	0.8	62
642	Effect of Propranolol on Pharmacokinetics and Acute Electrocardiographic Changes following Intravenous Quinidine in Humans. <i>Pharmacology</i> , 1978, 17, 301-306.	2.2	26
643	Effect of Abdominal Radiation Therapy on Drug Absorption in Humans. <i>Journal of Clinical Pharmacology</i> , 1978, 18, 388-396.	2.0	11
644	Impaired absorption of desmethyldiazepam from clorazepate by magnesium aluminum hydroxide. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 24, 308-315.	4.7	63
645	Cerebrospinal Fluid Digoxin Concentrations in Humans. <i>Journal of Clinical Pharmacology</i> , 1978, 18, 16-20.	2.0	8
646	Diazepam absorption: Effect of antacids and food. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 24, 600-609.	4.7	74
647	Kinetics of intravenous and intramuscular morphine. <i>Clinical Pharmacology and Therapeutics</i> , 1978, 24, 52-59.	4.7	223
648	Sex Differences in Diazepam Protein Binding in Patients with Renal Insufficiency. <i>Pharmacology</i> , 1978, 16, 26-29.	2.2	18

#	ARTICLE	IF	CITATIONS
649	Problems with Drug Interactions in Treating Brain Disorders. <i>Psychiatric Clinics of North America</i> , 1978, 1, 51-69.	1.3	7
650	Meprobamate Overdosage: A Continuing Problem. <i>Clinical Toxicology</i> , 1977, 11, 501-515.	0.5	28
651	Acute overdosage with benzodiazepine derivatives. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 497-514.	4.7	127
652	Evidence for Systematic Temporal Variation In 24-Hour Urinary Creatinine Excretion. <i>Journal of Clinical Pharmacology</i> , 1977, 17, 108-119.	2.0	12
653	Toxicity of high-dose flurazepam in the elderly. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 355-361.	4.7	224
654	Clinical pharmacokinetics of lorazepam; II. Intramuscular injection. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 21, 222-230.	4.7	44
655	Kinetics of intravenous chlordiazepoxide: Sex differences in drug distribution. <i>Clinical Pharmacology and Therapeutics</i> , 1977, 22, 893-903.	4.7	37
656	Clinical Pharmacokinetics of Lorazepam. III. Intravenous Injection. Preliminary Results. <i>Journal of Clinical Pharmacology</i> , 1977, 17, 490-494.	2.0	31
657	Absorption and Disposition of Chlordiazepoxide in Young and Elderly Male Volunteers. <i>Journal of Clinical Pharmacology</i> , 1977, 17, 709-718.	2.0	103
658	Pharmacokinetics and Clinical Effects of Amantadine in Drug-Induced Extrapyrmidal Symptoms. <i>Journal of Clinical Pharmacology</i> , 1977, 17, 704-708.	2.0	34
659	Clinical Pharmacokinetics of Lorazepam. IV. Long-Term Oral Administration. <i>Journal of Clinical Pharmacology</i> , 1977, 17, 495-500.	2.0	11
660	Clinical toxicity of furosemide in hospitalized patients. <i>American Heart Journal</i> , 1977, 94, 6-13.	2.7	57
661	Factors influencing blood concentrations of chlordiazepoxide: A use of multiple regression analysis. <i>Psychopharmacology</i> , 1977, 54, 277-282.	3.1	16
662	Adverse reactions to practolol in hospitalized patients. <i>European Journal of Clinical Pharmacology</i> , 1977, 12, 167-170.	1.9	11
663	Reduced Clearance of Quinidine in Elderly Humans. <i>Verhandlungen Der Deutschen Gesellschaft Fur Kreislaufforschung</i> , 1977, 43, 426-426.	0.1	2
664	Bioavailability of Drugs. <i>Clinical Pharmacokinetics</i> , 1976, 1, 36-51.	3.5	71
665	Variability of 24-Hour Urinary Creatinine Excretion by Normal Subjects. <i>Journal of Clinical Pharmacology</i> , 1976, 16, 321-328.	2.0	128
666	Clinical use and toxicity of intravenous lidocaine. <i>American Heart Journal</i> , 1976, 92, 168-173.	2.7	105

#	ARTICLE	IF	CITATIONS
667	Assessment of Methodology in Single-Dose Studies of Digoxin Bioavailability. <i>Pharmacology</i> , 1976, 14, 182-190.	2.2	11
668	Kinetics of high-dose intravenous morphine in cardiac surgery patients. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 752-756.	4.7	43
669	Clinical pharmacokinetics of lorazepam. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 329-341.	4.7	82
670	Plasma and cerebrospinal fluid concentrations of chlordiazepoxide and its metabolites in surgical patients. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 20, 571-578.	4.7	20
671	Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption. <i>Clinical Pharmacology and Therapeutics</i> , 1976, 19, 234-239.	4.7	48
672	Serum Creatine Phosphokinase Concentrations After Intramuscular Chlordiazepoxide and Its Solvent. <i>Journal of Clinical Pharmacology</i> , 1976, 16, 118-121.	2.0	17
673	Digitalis. <i>Postgraduate Medicine</i> , 1976, 59, 134-139.	2.0	1
674	Intramuscular Injection of Drugs. <i>New England Journal of Medicine</i> , 1976, 295, 542-546.	27.0	154
675	Accidental Iron Poisoning in Childhood. <i>Clinical Pediatrics</i> , 1976, 15, 835-838.	0.8	20
676	Flurazepam hydrochloride. <i>Clinical Pharmacology and Therapeutics</i> , 1975, 17, 1-14.	4.7	55
677	Role of Nurse and Pharmacist Monitors in the Boston Collaborative Drug Surveillance Program. <i>Drug Intelligence & Clinical Pharmacy</i> , 1975, 9, 648-654.	0.4	8
678	Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 1975, 3, 181-192.	0.6	122
679	Pharmacotherapy of Essential Hypertension. <i>American Journal of Health-System Pharmacy</i> , 1975, 32, 508-517.	1.0	1
680	Drugs Five Years Later. <i>Annals of Internal Medicine</i> , 1975, 83, 237.	3.9	39
681	Rational Use of psychotropic drugs IV. Antidepressants. <i>American Journal of Health-System Pharmacy</i> , 1975, 32, 59-64.	1.0	1
682	Chlordiazepoxide Metabolism in Mice following Hepatic Irradiation. <i>Pharmacology</i> , 1975, 13, 248-251.	2.2	4
683	Intravenous digoxin as a bioavailability standard. <i>Clinical Pharmacology and Therapeutics</i> , 1975, 17, 117-119.	4.7	5
684	Clinical Pharmacokinetics. <i>New England Journal of Medicine</i> , 1975, 293, 964-970.	27.0	207

#	ARTICLE	IF	CITATIONS
685	Clinical Pharmacokinetics. <i>New England Journal of Medicine</i> , 1975, 293, 702-705.	27.0	450
686	Rational Use of Psychotropic Drugs III. Major Tranquilizers. <i>American Journal of Health-System Pharmacy</i> , 1974, 31, 1226-1232.	1.0	1
687	Pharmacokinetic Determinants of the Response to Single Doses of Chlordiazepoxide. <i>American Journal of Psychiatry</i> , 1974, 131, 1395-1397.	7.2	7
688	Rational Use of Psychotropic Drugs II. Antianxiety Agents. <i>American Journal of Health-System Pharmacy</i> , 1974, 31, 1077-1084.	1.0	1
689	The clinical use of procainamide. <i>American Journal of Health-System Pharmacy</i> , 1974, 31, 889-894.	1.0	1
690	Rational use of psychotropic drugs. I. Hypnotics. <i>American Journal of Health-System Pharmacy</i> , 1974, 31, 990-1000.	1.0	6
691	Benzodiazepines. <i>New England Journal of Medicine</i> , 1974, 291, 1239-1243.	27.0	67
692	The Archaic Barbiturate Hypnotics. <i>New England Journal of Medicine</i> , 1974, 291, 790-791.	27.0	33
693	Slow Absorption of Intramuscular Chlordiazepoxide. <i>New England Journal of Medicine</i> , 1974, 291, 1116-1118.	27.0	53
694	Adverse Reactions to ??-Adrenergic Receptor Blocking Drugs. <i>Drugs</i> , 1974, 7, 118-129.	10.9	146
695	Comparison of one- and six-day urinary digoxin excretion in single-dose bioavailability studies. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 813-816.	4.7	16
696	Influence of serum digoxin concentration measurements on frequency of digitoxicity. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 284-287.	4.7	48
697	Bioavailability of digoxin tablets and elixir in the fasting and postprandial states. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 16, 444-448.	4.7	37
698	Intravenous digoxin as a bioavailability standard: Slow infusion and rapid injection. <i>Clinical Pharmacology and Therapeutics</i> , 1974, 15, 510-513.	4.7	31
699	Adverse reactions to propranolol in hospitalized medical patients: A report from the Boston Collaborative Drug Surveillance Program. <i>American Heart Journal</i> , 1973, 86, 478-484.	2.7	220
700	Anticholinergics. <i>New England Journal of Medicine</i> , 1973, 288, 1215-1219.	27.0	85
701	Evaluation of Digoxin Bioavailability in Single-Dose Studies. <i>New England Journal of Medicine</i> , 1973, 289, 651-654.	27.0	113
702	Chlorpromazine and Hyperpyrexia. <i>Clinical Pediatrics</i> , 1973, 12, 504-505.	0.8	9

#	ARTICLE	IF	CITATIONS
703	Which Drug for Alcohol Withdrawal?. The Journal of Clinical Pharmacology and New Drugs, 1972, 12, 429-431.	0.3	9
704	The Clinical Choice of Sedative-Hypnotics. Annals of Internal Medicine, 1972, 77, 91.	3.9	36
705	Psychopharmacologic Management of Anxiety in the Cardiac Patient. Psychiatry in Medicine, 1971, 2, 55-66.	0.4	3
706	Meprobamate: A Study of Irrational Drug Use. American Journal of Psychiatry, 1971, 127, 1297-1303.	7.2	37
707	Magnesium pemoline and job performance in mentally handicapped workers. Clinical Pharmacology and Therapeutics, 1969, 10, 530-533.	4.7	5
708	In Vitro Approaches to Anticipating Clinical Drug Interactions. , 0, , 31-74.		1
709	Drug-Drug Interactions, Second Edition. , 0, , .		8
710	Mechanisms and Consequences of Drug-Drug Interactions. , 0, , 879-917.		11